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1. Introduction 
 
Right ventricular hypertrophy and dysfunction are connected to several conditions including 
pulmonary hypertension (PH), congenital heart disease or valvular disease.  However, in the 
past, the importance of right ventricle (RV) function in health and disease has been often 
underestimated. In fact, for many years the emphasis in the literature was placed on  
the left ventricular physiology.  Only recently, in 2006, the National Heart, Lung and Blood 
Institute recognized the physiology of right ventricle as priority in cardiovascular research 
[1]. Nevertheless, a lot of insight has been achieved in the pathophysiology of LV function 
and one could assume most of the mechanisms should be common for both ventricles. Still 
one should keep in mind the developmental and structural differences of both. During 
development, the heart is formed from two distinct populations of cardiac progenitors. First 
heart field (FHF) progenitor cells exclusively contribute to the development of left 
ventricular myocardium while second heart field (SHF) cells contribute to development of 
outflow tract and right ventricular myocardium [2]. Additionally, right ventricle has different 
shape than the left ventricle. Whereas LV has ellipsoidal shape, the RV appears triangular 
(side view) and crescent shaped (cross section view). Right ventricle is also thinner than the 
left ventricle, which reflects the low hydraulic impedance characteristics of pulmonary 
vascular bed. Due to low pulmonary vasculature resistance right ventricle pumps the same 
effective stroke volume as the left ventricle but with approximately one fifth of the stroke 
work. Finally, compared with the LV, the RV demonstrates an elevated sensitivity to 
afterload change [3, 4]. Pulmonary hypertension is one of the essential causes of right 
ventricular remodeling. In fact right ventricle function is one of the major determinants of 
PH patients’ survival [5].  
1.1 Pulmonary hypertension 
 
Pulmonary hypertension is a condition characterized by vascular narrowing leading to  
a progressive increase in pulmonary vascular resistance, increase in the afterload and right 
heart hypertrophy and dysfunction. It is clinically defined as mean pulmonary arterial 
  
 
11 1. Introduction 
pressure (PAP) of more than 25 mm Hg at rest or 30 mm Hg during exercise, while normal 
PAP at rest comes to around 15 mm Hg [6, 7]. The causes of PH were classified according  
to the clinical diagnosis into 5 major groups:  i) pulmonary arterial hypertension (PAH, with 
idiopathic and familial PAH), ii) PH owing to left heart disease, iii) PH owing to lung diseases 
and/or hypoxia, iv) chronic thromboembolic pulmonary hypertension and v) PH with 
unclear multifactorial mechanisms [8]. According to a broad study in France the prevalence 
of PAH is 15 cases per million, with an average age of 50 ± 15 years at the time of diagnosis, 
a female predisposition of 2:1 and an average mean PA pressure of 55 mmHg [9]. Most 
patients with PAH present exertional dyspnea, indicating an inability to increase cardiac 
output. Other reported symptoms include: fatigue or weakness, syncope and angina 
pectoris which are indicative of right heart dysfunction [10]. Exertional intolerance is 
determined based on the classification of the World Health Organization (WHO) (see Table 
1). The estimated median survival of patients remains within a range of 2.8-4 years post 
diagnosis [5, 11].  
 
Class Description 
I Patients with pulmonary hypertension in whom there is no limitation of usual 
physical activity; ordinary physical activity does not cause increased dyspnea, 
fatigue, chest pain, or presyncope. 
II Patients with pulmonary hypertension who have mild limitation of physical activity. 
There is no discomfort at rest, but normal physical activity causes increased dyspnea, 
fatigue, chest pain, or presyncope. 
III Patients with pulmonary hypertension who have a marked limitation of physical 
activity. There is no discomfort at rest, but less than ordinary activity causes 
increased dyspnea, fatigue, chest pain, or presyncope. 
IV Patients with pulmonary hypertension who are unable to perform any physical 
activity at rest and who may have signs of right ventricular failure. Dyspnea and/or 
fatigue may be present at rest and symptoms are increased by almost any physical 
activity. 
Table 1:  World Health Organization classification of functional status of patients with pulmonary 
hypertension 
1.1.1 Pathogenesis of PAH 
 
A number of abnormalities underlie the pathogenesis of PAH including: i) formation  
of plexiform lesions and neointima ii) muscularization of distal precapillary arteries  
iii) medial thickening of large pulmonary muscular arteries [12], iv) adventitial thickening 
[13] and v) sustained vasoconstriction [14]. 
Intimal changes are largely responsible for narrowing of small pulmonary arteries  
and have potentially large impact on the pulmonary vascular resistance. Those changes may 
encompass eccentric, concentric and plexiform lesions. Eccentric proliferation  
or fibrosis in the intima usually occurs at any level of pulmonary vessels and causes only 
mild luminal obstruction. Concentric intimal proliferation on the other hand is mostly 
limited to small muscular arteries and arterioles and is typically associated with nearly 
complete luminal occlusion [15]. Plexiform lesions are complex, glomeruloid-like vascular 
structures, usually found distal to branch points of small- to medium-sized pulmonary 
arteries. They are composed of vascular channels lined up by endothelial cells and a core of 
myofibroblasts or less well-differentiated cells. These lesions are considered to be a 
hallmark of obstructive remodeling associated with severe PAH [16, 17] 
Arterial muscle layer typically comes up to around 10-15% of total vessel diameter  
in healthy individuals, while in PAH this value can be increased up to 60% [18]. However, 
structural changes within medial wall vary along longitudinal axis of pulmonary vessels.  
This is caused by differences in cellular composition along this axis. The main alterations 
include medial thickening of elastic and muscular proximal vessels as well as 
muscularization of small, previously non-muscularized vessels. In proximal vessels, medial 
hypertrophy occurs probably due to the proliferation of a distinct population of smooth 
muscle-like cells, which exist in relatively undifferentiated state [19, 20]. Hypertrophy of the 
media in the distal vessels, considered a characteristic feature of PAH, is most probably 
occurring due to cellular hypertrophy and hyperplasia and contribution of other cells [21]. 
An interesting alteration in the course of pulmonary hypertension is muscularization of 
small alveolar wall vessels. Several mechanisms were proposed to underlie this process 
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including recruitment of interstitial fibroblasts or extravasation of inflammatory and 
mesenchymal precursor cells [14, 22].  
Pulmonary hypertension is also characterized by significant fibroproliferative changes  
in the adventitial layer of both, large and small pulmonary arteries. Thickening of adventitia 
occurs as a result of excessive production and deposition of extracellular matrix (ECM) 
proteins (e.g., collagens), adventitial fibroblast proliferation and accumulation of 
myofibroblasts [14, 23]. Additionally adventitial thickening can also result from proliferation 
of resident and circulating progenitor cells. It has been shown that circulating mesenchymal 
precursors of a monocyte/macrophage lineage, including fibrocytes, can also contribute to 
pulmonary vascular remodeling [24]. 
 
Fig.1 Schematic representation of pulmonary artery structure and vascular remodeling observed 
in the progression of PAH: Presented on the left is the normal structure of pulmonary arteries 
consisting of tunica adventitia, external elastic lamina, tunica media, internal elastic lamina and 
endothelial layer. Several growth factors as well as the imbalance between vasodilators and 
vasoconstrictors may lead to the narrowing of pulmonary arteries lumen during vascular 
remodeling, presented on the right. This process includes: formation of neointima, hypertrophy of 
the muscular layer and thickening adventitial layer (Based on: Barst, RJ 2005)[25] 
 
Another mechanism contributing to the development of PAH is sustained vasoconstriction  
of pulmonary vessels in response to hypoxia. Hypoxic pulmonary vasoconstriction (HPV) is  
an adaptive response to alveolar hypoxia allowing optimizing the matching between 
ventilation and perfusion and thus improving gas exchange. In normal conditions 
vasoconstriction occurs within seconds after exposure to moderate hypoxia and reverses 
quickly under normoxic conditions. However, in people exposed to chronic hypoxia  
(e.g. high-altitude residents) global vasoconstriction throughout the pulmonary circulation  
is observed leading to increased PVR [26]. Chronic hypoxia can further lead to structural 
changes in pulmonary vasculature and to the development of PH [27]. One of the 
underlying mechanisms observed in both, chronic hypoxic PH as well as PAH is activation of 
hypoxia-inducible factor 1α (HIF1α) and nuclear factor of activated T cells (NFAT) 
transcription factors, decreasing Kv1.5 expression [28]. 
 
1.2 Cardiac remodeling  
 
Cardiac remodeling refers to changes in size, shape and function of the heart triggered  
by cardiac injury. It is a progressive disorder which may be connected to myocardial 
infarction (MI), pressure overload (hypertension), inflammatory heart muscle disease 
(myocarditis), idiopathic dilated cardiomyopathy or volume overload (valvular 
regurgitation). As the heart remodels, changes in its geometry, ventricular mass, 
composition and volume occur [29]. This process involves cellular changes including 
myocyte hypertrophy, increased collagen synthesis, fibroblast proliferation and 
cardiomyocyte apoptosis [30-33].  Irrespective of the underlying causes of cardiac 
remodeling, this condition progresses and is highly correlated with mortality from 
cardiovascular disease [34]. 
 
1.2.1 Cardiac hypertrophy 
 
The preservation of normal hemodynamics in patients suffering from heart failure and PAH 
depends on stable function of the heart. Sustained demands on the heart can result  
in development of cardiac hypertrophy. Meerson described three stages of cardiac 
hypertrophy caused by aorta stenosis:  “transient breakdown stage” occurring directly after 
stenosis with left ventricular insufficiency and pulmonary congestion, “protracted stage”  
of relatively stable “hyperfunction” and the third stage of progressing cardiosclerosis (with 
fibrotic changes and cardiac insufficiency) [35]. Cardiac hypertrophy can occur in response  
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to different stimuli. It can be triggered by chronic exercise (physiological hypertrophy) and 
diverse disease conditions (pathological hypertrophy). Intensive training for instance,  
can lead to the development of left ventricular hypertrophy. Changes observed in athletes 
include increase in left ventricular chamber size, wall thickness and mass and their 
advancement and general properties may depend on the type of exercise (endurance 
versus strength exercise). Nevertheless, physiological hypertrophy is associated with 
preserved function of the heart [36].  Pathological hypertrophy, on the other hand, is 
accompanied by various molecular changes leading to cardiac dysfunction. It is now known 
that distinct signaling cascades can be activated in those conditions (e.g. IGF-PI3K vs. ANGII,  
ET-1/Calcineurin, NFAT) [37].  
Thus, the right ventricle may initially adapt to increased afterload [38]. During the initial 
escalation in afterload, the increase in right ventricular end diastolic volume helps  
to preserve cardiac output, in accordance with Frank-Starling mechanism. To reduce the 
wall stress and allow maintaining an appropriate stroke volume, the right ventricle 
undergoes hypertrophy.  [39]. Following the Laplace’s law, where an increase in ntraluminal 
pressure of a thin-walled chamber results in an increase in wall stress (Fig.2).  
 
Fig.2 Right ventricular structure in normal conditions and in right ventricular hypertrophy: 
According to Laplace’s law, increased RV wall stress (σ) due to an elevated intraluminal pressure (P) 
and increased chamber radius (r) may be attenuated by increasing the right ventricular wall 
thickness (h)(Based on: Bogaard, HJ et al., 2009)[40] 
This wall stress can be reduced by either an increase in the wall thickness or by reducing 
internal radius of the chamber. 
Myocardial hypertrophy induced by the increase in afterload occurs mainly by increasing 
the size of the cells, the addition of sarcomeres and protein synthesis [41-43]. Apart from 
mechanical stress, right ventricular adaptation to the pressure load is a complex process 
and may also depend on several other factors, e.g. myocardial fibrosis [44]. Although 
cardiac hypertrophy is thought to be beneficial, sustained long-term pressure overload is 
eventually leading to right ventricular dilatation. This process is characterized by 
contractility dysfunction of the right heart, unbalanced ratio of oxygen supply to the 
demand and structural changes within the myocardium (e.g. fibrosis, cardiomyocyte 
apoptosis). Increased ventricular volume may further lead to tricuspid regurgitation 
resulting in right ventricular volume overload and further influencing the right ventricle 
remodeling [45]. A dilated right ventricle can shift the interventricular septum resulting in 
an impaired left ventricular filling [46]. These processes, together with right ventricular 
dysfunction are the components contributing to the development of heart failure.  
 
 
Fig.3 Interventricular septum shift during right ventricular dilatation: Dilated right ventricle shifts 
interventricular septum towards left contributing to the change of left ventricular geometry and its 
underfilling. This leads to decrease in cardiac output in patients with severe PAH. (Based on: 
Haddad, F et al. 2008)[47]. 
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1.2.2 Cardiac fibroblasts and myocardial fibrosis 
 
The non-myocyte cell populations of the heart are increasingly appreciated to contribute to 
the function of the normal and failing heart. In fact, the normal adult human heart 
comprises of only 30% cardiomyocytes and 70% non-myocyte cells [48]. Cardiac fibroblasts 
(CFs) have been described as the major component of non-myocyte cell fraction of the 
heart. They are arranged in a 3D network that surrounds myocytes and other cell types. A 
network of fibrillar collagen provides scaffolding for cardiomyocytes and other cells. 
Individual muscle fibers are surrounded by endomysial collagen, which is interspersed with 
single cardiac fibroblasts. The endomysium serves also as scaffolding for blood vessels. 
Perimysial strands further surround the muscle fibers and finally the entire muscle is 
strengthened and wrapped by a coarse epimysium [49, 50](Figure 4, left).  
 
Fig. 4 Schematic representation of changes in the collagen network due to hypertension:  
In the normal heart, muscle fibers are surrounded by thin layers of endo- and perimysium with 
single interspersed fibroblasts (left). In cardiac hypertrophy, an excessive deposition of ECM proteins 
as well as fibroblast proliferation occurs, leading to perivascular fibrosis and fibrosis of the 
endomysium and perimysium (right)(Based on: Berk, B.C. 2007)[51]. 
 
Cardiac fibroblasts play an important role in preserving the structure of cardiac tissue. They 
are responsible for (i) synthesis and deposition of ECM components, (ii) ECM degradation 
and turnover through synthesis and release of matrix metalloproteinases (MMPs), and (iii) 
the generation of mechanical stress on epimysial collagen network [32]. Cardiac ECM is 
composed mainly of three types of collagen, namely types I, III and V, which constitute 
almost 90% of the entire portion of collagen.  
Collagen type I and III are major components of the network of collagen fibers. Their 
relative proportion is thought to influence the physical properties of the heart. Type I 
collagen forms mainly thick fibers and is associated with tensile strength. Type III collagen, 
in turn, forms a fine network of fibers and is associated with tissue elasticity. Other 
collagens found in the heart are type IV, V and VI which are found in basement membranes, 
interstitium and vessels [52].  
During the initial phase of pressure overload, the synthesis of collagen increases in 
proportion to the increase in heart weight. The existing collagen matrix becomes thicker 
and denser. This process allows the heart muscle to become a more efficient power 
generator. Another important feature is the accumulation of thick collagen fibers around 
small coronary arteries (Figure 5, right). In established hypertrophy thin collagen fibers 
increase in the intermuscular space. Thick collagen fibers become entwined in the thin 
filaments (later only thick filaments are visible). This particular remodeling of collagen 
matrix has a great effect on myocardial stiffness. Muscle fibers are not easily stretched in 
diastole, this limits the length dependent force generation. Such a pattern of myocardial 
fibrosis may therefore be responsible for the conversion of compensated to 
decompensated heart function and for manifestation of pathological hypertrophy in long-
term pressure overload. Another pattern of myocardial fibrosis is observed in the late phase 
of established hypertrophy. It is clearly initiated in response to cell death. The presence of 
fibrosis has a reparative role and leads to replacement scarring. Systolic and diastolic 
stiffness are increasing [49]. 
The excess of collagen in the myocardium observed in the right ventricular hypertrophy 
(RVH) is a result of both, increased collagen synthesis and decreased collagen degradation 
[30]. Extracellular matrix remodeling also includes an increased expression of specific matrix 
metalloproteinases (MMPs) and their inhibitors in the myocardium that are associated with 
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the progression to heart failure [53]. This process is associated with reduced collagen cross-
linking caused by the activity of MMPs [54]. Fibroblast proliferation, collagen synthesis as 
well as expression and activation of MMPs can be induced by several molecules that are 
elevated in pulmonary hypertension, including the renin-angiotensin system and cytokines 
[32]. Since fibroblasts can respond to a wide range of humoral factors, they may become  
a new target for development of new therapeutic approaches against heart failure. 
 
1.3 Mechanical stress and signaling in hypertrophic response 
 
1.3.1 Integrins  
 
Changes in afterload are sensed by integrins, the heterodimeric transmembrane receptors 
interacting with ECM components and cytoskeleton proteins. Integrins have several 
functions in the cell that include: regulation of cellular phenotype, adhesion, migration and 
most interestingly they serve as mechanotransducers and thus serve an important role in 
hypertrophic response. The onset of pressure overload seems to be accompanied by 
coordinated changes in expression profile and localization of integrins and ECM [55]. 
Integrins shedding into extracellular space has been observed during transition from cardiac 
hypertrophy to dilatation, which seems to be important process allowing cardiac cells to 
change their size and shape [56]. Furthermore, mechanical stress sensing by integrins 
results in intracellular signaling. It has been shown that the pressure overload triggers 
integrin activation and focal assembly of signaling proteins, including focal adhesion kinase 
(FAK) and Src in pulmonary artery banded (PAB) cat model. Also signaling through 
extracellular signal-regulated kinases (ERK1/2) and phosphatidylinositol 3-kinases (PI3Ks) 
has been reported in hypertrophied myocardium [57, 58].  
 
 
1.3.2 Renin-Angiotensin system  
 
One of important factors influencing cardiac hypertrophy is the renin-angiotensin system 
(with its primary effector molecule – angiotensin II; Ang II). Angiotensin II primarily 
regulates salt/water homeostasis and vasoconstriction thus regulating blood pressure, 
however long-term exposure to Ang II plays an essential role in cardiac hypertrophy and 
remodeling. In response to reduced perfusion, juxtaglomerular cells in the kidney secret 
renin that cleaves angiotensinogen to angiotensin I (Ang I). Subsequently Ang I is converted 
to Ang II by angiotensin converting enzyme (ACE) [59]. Angiotensin II has been shown to 
have direct growth effect on left ventricle in response to pressure overload [60].  This effect 
is mediated by angiotensin type 1 receptor (AT1R) as administration of its antagonist 
diminishes Ang-II-induced cardiac hypertrophy [61]. In the right ventricular hypertrophy an 
increased density of AT1R along with reduced contractility was observed in response to Ang 
II. Treatment with ACE inhibitor, ramipril has been shown to have cardioprotective effect 
supporting the idea that increased local levels of Ang II may cause receptor desensitization 
[62]. 
 
1.3.3 Endothelin-1 
 
Endothelins belong to a family of peptides which includes endothelin-1, endothelin-2 and 
endothelin-3 (ET-1, ET-2 and ET-3, respectively). Endothelin-1 is the main isoform expressed 
in the vasculature where it acts as a potent vasoconstrictor. The main function of ET-1 is the 
regulation of blood pressure and vascular tone. The main sources of ET-1 generation are the 
endothelial cells, but ET-1 (as well as ET-2) can also be produced by the myocardium. 
Endothelin is mainly considered as a locally acting paracrine factor. Nonetheless, venous 
plasma concentration of ET-1 can be used as a marker for peptide synthesis by the vascular 
endothelium [63]. Endothelin-1 exerts its biological effects through two isoforms of  
G protein-coupled receptors, namely, endothelin receptor A (ETA) and endothelin receptor 
B (ETB). Both are expressed within the pulmonary vasculature and in cardiac muscle [64, 65]. 
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ET-1 may contribute to the pathophysiology of PH and heart failure, particularly through its 
vasopressor properties. Furthermore, it may interact with other neuroendocrine effectors 
such as angiotensin II and catecholamines [66]. In addition to its vascular effect, endothelin-
1 may also exert direct effects on the heart. It is well known that ET-1 has a positive 
inotropic effect on the human myocardium. In studies on neonatal cardiomyocytes it has 
been shown that ET-1 can be locally produced by the heart in response to angiotensin II and 
contribute to cardiac hypertrophy [67]. This effect may be due to stimulation of contractile 
protein production by cardiomyocytes [68] as well as the proliferation of cardiac fibroblasts 
[69]. In humans,  increased levels of ET-1 were observed in a failing myocardium [70].  
 
1.3.4 Calcineurin and NFAT signaling 
 
Variety of humoral factors triggering hypertrophic response (e.g. Ang II, ET-1) is signaling 
through elevation of intracellular Ca2+ levels. This signal is sensed by calmodulin-dependent 
phosphatase – calcineurin. Calcineurin is a dimeric protein that is activated by binding to 
calmodulin when it is saturated with Ca2+. It directly binds to and dephosphorylates NFAT 
transcription factors. This in turn allows their nuclear translocation and triggering of 
hypertrophic response genes. In fact activated NFAT3 transcription factor has been shown 
to be necessary and sufficient to evoke cardiac hypertrophy [71]. Additionally, calcineurin-
NFAT signaling can be modulated by cross talk with other signaling pathways. For example it 
has been described that glycogen synthase kinase 3β (GSK3β) can induce phosphorylation 
of NFAT in cardiac fibroblasts [72]. 
 
1.4 Gene expression changes in cardiac hypertrophy 
 
Cardiac hypertrophy is not simply an increase in diameter of myocytes and fibrosis, but it 
also promotes changes in gene expression profile in the myocardium. These changes can be 
both qualitative and quantitative. Interestingly, it is believed that in the pressure-
overloaded hearts a re-expression of neonatal genes is triggered [73].  
One of the hallmarks of maladaptive cardiac hypertrophy is the isoform switching of myosin 
heavy chain (MHC) proteins. Cardiac sarcomeric thick filaments may be composed of two 
different MHC isoforms, namely αMHC and βMHC. Myosin isoforms comprised from αMHC 
or βMHC demonstrate marked mechanical and enzymatic differences. The βMHC isoform 
has lower adenosine triphosphate activity and contraction velocity [74]. In adult human 
heart the amount of αMHC and βMHC comes to approximately 23% and 77%, respectively. 
In heart failure due to PAH, this ratio is disturbed and αMHC drops to about 5.6% and an 
increased percentage of βMHC observed. Given the differences in shortening velocity of 
both isoforms, such decrease in αMHC can contribute to lowering of cardiac systolic 
function observed in PAH [75]. Sustained pressure overload can also trigger changes in 
expression of genes encoding thin filament proteins. Two α-actin isoforms are expressed in 
adult hearts: α-skeletal muscle actin (αSKA) and α-cardiac actin (αCAA). In hypertrophied 
myocardium due to pressure overload an increase in the expression of αSKA and α-smooth 
muscle actin (αSMA) was reported, both in human and in animal models [76-78]. 
The changes in gene expression profile in response to increased afterload are not only 
limited to components of the contractile apparatus. In the disease progression of PH, 
natriuretic peptides were shown to play an essential role. The family of cardiac natriuretic 
peptides consists of atrial (ANP), brain (BNP) and C-Type natriuretic peptides, of which ANP 
and BNP are synthesized and secreted into circulation by the heart. The cardiac natriuretic 
peptides are synthesized as high molecular weight precursors and therefore have to 
undergo multiple steps involving proteolytic cleavage before yielding the biologically active 
molecules. Upon binding to their receptors (NPR-A and NPR-C) the particulate guanylate 
cyclase, produces cyclic guanosine monophosphate, which further acts as the intracellular 
messenger. ANP is mainly released from atria, whereas BNP produced in ventricular 
cardiomyocytes. Their expression and release is triggered by increased ventricular stretch, 
but this response is modulated by many other factors, such as ATII, ET-1 or circulating 
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catecholamines [79]. Indeed, an upregulation of ANP and BNP expression in the right 
ventricle has been reported in pulmonary artery banding model [31]. Moreover plasma 
levels of both natriuretic peptides were elevated in patients suffering from PAH showing a 
strong positive correlation with total pulmonary resistance and RV end-diastolic pressure. 
Interestingly, in patients receiving prostacyclin therapy follow-up BNP plasma level was an 
independent predictor of mortality in PAH. Thus, plasma BNP levels may serve as  
a noninvasive prognostic indicator of PAH [80].  
Many other signaling pathways and deregulation of gene expression underlies maladaptive 
cardiac growth, which do not fall within the scope of this dissertation. For other pathways 
the reader is referred to some excellent reviews [40, 72, 73]. The summary of key changes 
in the right ventricular hypertrophy is represented in Figure 5. 
 
 
 
Fig. 5 Gene expression changes during pressure-induced cardiac hypertrophy: A summary of 
essential molecular changes during progression of right ventricular hypertrophy is depicted; α-CAA – 
α-cardiac actin, α-MHC – α-myosin heavy chain, α-SKA – α-skeletal actin, α-SMA –  
α-smooth muscle actin, ANP – atrial natriuretic peptide, β-MHC – β-myosin heavy chain,  
BNP – brain natriuretic peptide, MMPs – matrix metalloproteinases (Based on: Boheler and 
Schwartz 1992)[73] 
 
1.5 Current strategies in treatment of PAH and right heart failure 
 
Despite the successful introduction of several new pulmonary-selective vasodilatory 
therapies in the last decade, the prognosis of PAH patients still remains poor. It is important 
to note that it is the failing right ventricle itself (not the load per se) that leads to death. The 
treatment strategy for PAH should definitely consider the origin of RV failure. The aims of 
therapy include optimization of preload, afterload, and contractility [47]. 
Aside from the therapy, some general lifestyle modifications are advisable for PAH patients 
including low-sodium diet. Fluid retention can be further minimized by application  
of diuretics. Patients should be encouraged to low-grade exercises within symptom limits. 
One of utilized therapies in PAH is prostacyclin administration, as dysregulation of the 
prostacyclin metabolic pathways has been shown in patients with PAH. Besides continuous 
intravenous epoprostenol infusions, prostacyclin analogs were developed including 
subcutaneous treprostinil, oral beraprost and inhaled iloprost. Since endothelin is  
an important factor influencing PAH (see 1.3.3), also targeted therapies against this 
molecule have been developed. Bosentan, an orally available dual ETA and ETB receptor 
antagonist, has been evaluated in PAH in five randomized clinical trials that have shown 
improvement in exercise capacity, functional class, hemodynamics, and time to clinical 
worsening [81]. Also phosphodiesterase-5 (PDE-5) inhibitors have been approved for the 
treatment of pulmonary hypertension, as PDE5 is induced in the remodeled pulmonary 
arteries. Inhibition of the cGMP-degrading PDE-5 results in local vasodilatation through the 
activation of nitric oxide/cGMP pathway at sites expressing this enzyme. Interestingly, PDE5 
inhibitors have also been shown to target specifically the right ventricle. While the 
expression of PDE5 is minimal in the normal RV, its expression is markedly induced in the 
hypertrophied right ventricles of rats and humans. In addition to the positive effect of PDE-5 
inhibitors on afterload by dilating and reversing the remodeled pulmonary arteries, they 
were also found to have positive inotropic effect on the hypertrophied RV [82]. Inhibition of 
the angiotensin system and β-blockers may be considered in selected patients, although 
their benefit remains unclear and controversial [82]. Lung transplantation remains as a 
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mainstay for individuals that do not respond to available therapies. Additionally, numerous 
compounds are currently undergoing phase II and III clinical trials, namely stimulators and 
activators of cGMP, tyrosine kinase inhibitors and serotonin antagonists [81]. Despite the 
progress in the development of therapeutic strategies against PAH, the survival of patients 
remains unsatisfactory. Hence, there is a need to develop additional therapeutic options 
targeting specifically the heart in order to improve symptoms and further prognosis. 
 
1.6 Wnt signaling pathway 
 
Wnt (Wingless and INT-1) signaling pathway is essential for animal development and has 
been associated with several diseases, most likely by influencing cell proliferation, survival, 
fate and behavior [83]. Wnts are cysteine-rich proteins that undergo glycosylation and lipid 
modifications prior to its secretion. Nineteen Wnt genes have been identified in humans, 
whose orthologs have highly conserved sequences among different species of vertebrates 
[84, 85]. Wnt molecules are thought to activate a number of different signaling pathways. 
These molecules have been historically divided into two classes – canonical Wnts (activating 
β-catenin-dependent pathway, including Wnt1 or Wnt3A) and non-canonical Wnts 
(activating β-catenin-independent pathway, including Wnt5A or Wnt11). However, in light 
of present knowledge, it seems that it’s not the Wnt molecules who decide about the 
activation of canonical versus non-canonical pathways but the repertoire of their different 
receptors [86]. Indeed, Wnt proteins have been reported to interact with several classes of 
receptors [87].  
First and probably best known class of Wnt receptors are members of the Frizzled (Fz) 
family. Frizzleds are seven transmembrane-spanning receptors that belong phylogenetically 
to the family of G protein-coupled receptors. Ten Fz family members have been described 
to date in mammals. Frizzled receptors mediate activation of three major signaling 
pathways: the canonical Wnt pathway, calcium (Ca2+)-dependent pathway, and PCP (planar 
cell polarity) pathway (Figure 6).  
  
Fig. 6 The current sensing model of Wnt signaling via different receptors: Frizzled receptors 
mediate activation of three major signaling pathways: the β-catenin-dependent pathway (with the 
involvement of Lrp co-receptors), (Ca2+)-dependent pathway, and planar cell polarity (PCP) pathway. 
Also signaling through tyrosine kinase receptors from Ryk and Ror family has been described. (based 
on: van Amerongen et al. 2008)[86] 
 
In addition, a number of secreted proteins antagonizing Wnt signaling are observed in the 
extracellular matrix. They can be divided into two functional classes, soluble frizzled related 
proteins (sFRP) class and the Dickkopf (Dkk) class. Members of the first class bind directly to 
the Wnts, thereby altering their ability to bind to their receptor. These particles are 
considered to antagonize both, Wnt canonical and non-canonical signaling. The family 
members of Dkk, inhibit Wnt signaling by binding to LRP5/6 component of the Wnt receptor 
complex, which mainly antagonizes the canonical pathways [88].  
 
1.6.1 Wnt canonical signaling 
 
Canonical (or Wnt/β-catenin) signaling pathway is probably the best understood among all 
types of Wnt signal transduction. The hallmark of this pathway is the accumulation and 
nuclear translocation of β-catenin [89]. There are two pools of β-catenin existing in the 
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cells. A membrane-bound pool represents stable β-catenin and is located in cellular 
adherens junctions where it binds to E-cadherin and α-catenin. A soluble pool represents 
highly unstable cytoplasmic β-catenin involved in Wnt signal transduction [90].  The stability 
of cytoplasmic β-catenin levels is regulated by degradation complex comprised of glycogen 
synthase kinase 3 (GSK3), casein kinase 1 (CK1), Axin and adenomatous polyposis coli (APC). 
In this complex Axin seems to be a key scaffolding molecule promoting its rapid assembly 
and disassembly whereas APC is required for efficient loading of β-catenin onto the 
complex. Both facilitate the sequential phosphorylation of β-catenin by CK1 and GSK3 at 
highly conserved serine/threonine residues. This leads to its ubiquitylation by β-TrCP 
containing E3 ligase and subsequent proteasomal degradation (Figure 7) [91].   
 
 
Fig. 7 Canonical Wnt Signaling: In the absence of Wnt ligands (left panel) β-catenin is 
phosphorylated by CK1 and GSK3α/β leading to its subsequent ubiquitylation and proteasomal 
degradation. Prospective Wnt target genes remain in a repressed state. During activation of Wnt 
signaling (right panel), Dvl proteins undergo phosphorylation and are translocated to the cell 
membrane to interact with Fz receptors. LRP 5/6 co-receptors are also phosphorylated by GSK3β 
and CK1γ, thus regulating the docking of Axin. The recruitment of Axin away from the degradation 
complex leads to the accumulation of β-catenin in the cytoplasm and its subsequent nuclear 
translocation. In the nucleus, β-catenin binds to T-cell factor (TCF) and lymphoid binding protein 
(LEF)-family transcription factors and activates transcription of target genes. (based on: Clevers, H. 
2006)[91] 
 
The binding of Wnt molecules to their Fz/LRP5/6 receptor complex recruits Axin, the key 
negative regulator of signaling, to the cell membrane where it interacts with LRP  
co-receptors. The translocation of Axin to the cell membrane is enabled by GSK3β- and 
CK1γ- mediated phosphorylation of LRP5/6. Since Axin is present in cells at low levels, its 
sequestration to the membrane might compete with its function in the degradation 
complex, thereby allowing stabilization of β-catenin. It is noteworthy that in the presence of 
Wnt, GSK3ß can also fulfill a positive function in Wnt signal transduction. In the presence of 
Wnt signaling Dishevelled is recruited to the plasma membrane, precisely to the Fz 
receptors.  
Dvl is phosphorylated by number of kinases (including CK1) and most probably its 
phosphorylation status is regulating its subcellular localization. It has been shown that 
activation of Dvl facilitates the inactivation of degradation complex but the underlying 
mechanism remains elusive. This may likely occur through association of Dvl with Axin [87]. 
In fact it has been proposed that upon Wnt signaling and recruitment of Dvl to Frizzled 
receptors this protein forms polymers. These polymers  provide a dynamic scaffold for 
recruitment and inactivation of Axin [92]. Stabilized β-catenin accumulates in the cytoplasm 
and translocate into the nucleus (although β-catenin itself has no nuclear localization 
sequence). Here, it binds to T-cell factor (TCF) and lymphoid binding protein (LEF)-family 
proteins to co-activate the transcription of Wnt target genes, e.g. c-Myc or Cyclin D1 [91]. 
Interestingly, TCFs alone are incapable of modulating transcription. Instead, they recruit  
a number of auxiliary proteins to the regulatory regions of target genes. In the absence of 
Wnt signaling, TCF/LEF proteins function as transcriptional co-repressors by binding of the 
Groucho family proteins and recruiting histone deacetylases [93]. Activation of Wnt target 
genes occurs through direct competition of ß-catenin and Groucho for binding to TCF/LEF 
proteins [94]. After binding of TCF/LEF proteins, β-catenin engages the assistance of 
CBP/p300 and Brg1-containing complexes in the transcriptional activation of target genes 
(e.g. Cyclin D1, c-Myc) [93]. 
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1.6.2 Wnt non-canonical pathways 
 
The least understood aspect of Wnt signaling is β-catenin independent pathways termed as 
non-canonical signaling. It has been suggested that vertebrate non-canonical Wnt signaling 
might be involved in various processes as cochlear hair cell morphology, cardiac 
development, dorsoventral patterning, neuronal migration, and cancer. Wnt non-canonical 
pathways are mediated by binding of certain Wnts to Frizzled receptors independently of 
LRP5/6 co-receptors. This leads to the activation of Disheveled and further signal 
transduction via two distinct signaling pathways: Planar Cell Polarity pathway (PCP) and 
Wnt/Ca2+ pathway.  [95].  
Planar cell polarity pathway controls the orientation of hairs, bristles, and in vertebrates, 
stereocilia in the sensory epithelium of the inner ear, by regulating the actin cytoskeleton.  
In this pathway Dvl is activating two parallel signaling cascades via small GTPases Rho and 
Rac. This in turn activates JNK or rho-associated protein kinase. Wnt/Ca2+ signaling leads to 
release of Ca2+ from intracellular stores and activates calcium-sensitive proteins including 
protein kinase C, Calcineurin and Calcium- and Calmodulin-dependent kinase II. These 
kinases control independently other proteins and transcription factors (e.g. NFAT), thus 
regulating many cellular processes including cytoskeletal organization, cell polarity and 
motility [89]. 
 
1.7 Wnt signaling in cardiac hypertrophy 
 
Several intracellular pathways have been implicated in the development of cardiac 
hypertrophy (see chapter 1.3). Recently, the importance of Wnt signaling in this 
pathological process has received considerable interest. This signaling pathway is crucial for 
the development and has been implicated in several diseases [83]. Depletion of β-catenin 
results in embryonic lethality [96]. Mice lacking GSK3β (but not GSK3α) die during 
embryonic development due to heart defects [97]. Moreover Wnt canonical signaling has 
been shown to have a fundamental role in the development of SHF and promotes right 
ventricular and interventricular myocardial expansion [98]. To date, the literature on the 
role of the Wnt pathway is derived exclusively from studies on left ventricular hypertrophy. 
It has been demonstrated that in rats subjected to aortic banding and in porcine model of 
chronic heart failure, Dvl1 protein levels are increased. Overexpression of Dvl1 led to the 
development of maladaptive cardiac hypertrophy via both, canonical and non-canonical 
Wnt pathways [99]. On the other hand in mice lacking Dvl-1, the hypertrophic response 
induced by aortic constriction was attenuated as shown by decreased left ventricular wall 
thickness and decreased expression of ANP and BNP. In those mice an increased activity of 
GSK3β and decreased β-catenin levels were observed [100].  
 
1.7.1 The role of GSK3β 
 
Glycogen synthase kinase 3β (GSK3β) has been described to be a potent anti-hypertrophic 
agent and its role in cardiac hypertrophy has been extensively investigated. As previously 
mentioned GSK3β plays a fundamental role in normal heart development. Deletion of 
GSK3β leads to hyperproliferation of cardiomyocytes and death of mice caused by heart 
malformations whereas mice lacking GSK3α are born without obvious cardiac 
developmental defects. It has been postulated that this effect is most likely β-catenin 
independent [97]. Concerning cardiac hypertrophy, a decreased kinase activity of GSK3β has 
been detected in response to hypertrophic stimuli both in vitro and in vivo. This inhibition 
seemed to be important for the enhanced protein accumulation and ANP expression by 
cardiomyocytes [101]. On the other hand, when GSK3β is overexpressed, the development 
of concentric hypertrophy is attenuated. This results in impaired contractile function of the 
heart and may progress to the heart failure [102]. Interestingly, in human hearts, inhibition 
of GSK3β was seen in the end-stage of heart failure, but was not observed in chronic 
hypertrophy. The authors speculate that GSK3β downregulation could protect cells from 
apoptosis and allow NFAT to enter the nucleus to activate hypertrophic response genes 
[103]. 
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1.7.2 The role of β-catenin 
 
Although β-catenin has been recognized as an important factor of maladaptive cardiac 
growth, its exact role in this process remains controversial. β-catenin is stabilized upon 
hypertrophic stimuli, which involves the inhibition of GSK3β kinase activity.  β-catenin alone 
was sufficient to induce hypertrophic growth when expressed in cardiomyocytes in vitro 
and in vivo [104]. In addition, it has been found that targeted depletion of β-catenin in the 
heart leads to a blunted hypertrophic in response to transaortic constriction. The authors 
speculated this effect is attributable to β-catenin transcriptional co-activation properties as 
expression of a dominant inhibitory mutant of Lef-1 caused dramatic reduction in 
cardiomyocyte growth [105]. However, an opposite role of β-catenin in cardiac hypertrophy 
was also reported. Baurand et al. found that in the absence of hypertrophic stimuli, mice 
lacking β-catenin develop adaptive hypertrophy whereas stabilization of β-catenin results in 
slightly decreased cardiomyocyte cross-sectional area. Two weeks of AngII infusion did not 
affect further the hypertrophy in β-catenin-depleted mice, whereas mice with stabilized  
β-catenin displayed impaired hypertrophic response [106]. Overall, these observations lead 
to the conclusion that β-catenin has the potential to regulate cardiac hypertrophy, which 
may (at least in the experimental approach) depend on the type of hypertrophic stimulus. 
Future studies need to address the precise role of β-catenin in this pathological process.   
In conclusion, Wnt signaling pathway plays an important role in left ventricular remodeling 
in response to hypertrophic stimuli. While all of the available literature describes the impact 
of this signaling cascade in maladaptive growth of the left ventricle, its role in the right 
heart hypertrophy is thus far unknown.  
  
2. Aims of the study 
 
Considering the role of Wnt signaling in left ventricular remodeling, we hypothesized that it 
plays a crucial role in the development of right heart hypertrophy. As this pathway is 
essential for the development of right ventricle we speculated its contribution to RVH could 
be more prominent. The main aims of this study focused on: 
a) To define Wnt molecules expression on mRNA and protein levels in two animal models: rat 
monocrotaline (MCT) pulmonary hypertension model and pulmonary artery banding (PAB) 
model of right ventricular hypertrophy 
b) To determine mRNA expression of key molecules of Wnt canonical pathway,  
β-catenin and GSK3β in cardiac fibroblasts  
c) To characterize cardiac fibroblasts derived from right and left ventricles PAB and Sham 
operated rats 
d) To elucidate the influence of Wnt3a stimulation on β-catenin localization  
e) To determine if Wnt3a stimulation or β-catenin siRNA-mediated knockdown can influence 
cardiac fibroblast proliferation and collagen expression 
f) To investigate Wnt pathway activation in vivo in BAT-Gal reporter mice 
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3. Materials and Methods 
3.1 Materials 
3.1.1 Equipment 
 
Name Company 
Analytical balance Sartorius, Germany 
Biological safety cabinet, Cellgard NuAire, USA 
Cell culture Incubator, Hera Cell Thermo Scientific, USA  
Cell culture pump Integra Biosciences, 
Switzerland 
Cell culture waterbath Memmert, Germany 
Centrifuge – Heracell S Fresco 21 Thermo Scientific, USA 
Centrifuge, Heraeus Multifuge Thermo Scientific, USA 
CFX96 Real Time System  BioRad, USA 
Confocal Microscope, LSM 710 Carl Zeiss, Germany 
Cryotome Leica CM3050S Leica, Germany 
DNA electrophoresis unit, Compact M Biometra, Germany  
Freezer (+4°C, -20°C) Bosh, Germany 
Freezer (-80°C) New Brunswick Scientific, USA 
FujiFilm LAS-4000 FujiFilm, Japan 
Gel iX Imager Intas, Germany 
Infinite 200 PRO multiplate reader Tecan, Switzerland 
Ligth microscope Hund, Germany 
Magnetic stirrer Heidolph, Germany 
PCR Thermocycler Eppendorf, Germany 
pH meter Shott Instruments, Germany 
Pipetboy and Pipettes Eppendorf, Germany 
Polyacrylamide gel electrophoresis unit  Biorad, USA 
Power supply – PowerPac Basic Biorad, USA 
Precellys homogenizer Peqlab, Germany 
Precision balance EK-300i A&D, Japan 
Protein blotting chamber Biorad, USA 
Shaker, unimax 2010 Heidolph, Germany 
Thermoblock Bioer, China 
Vortex Scientific Industries, USA 
 
3.1.2 Plasticware and other materials 
 
Name Company 
Amicon Ultra centrifugal filter units Millipore, USA 
Disposable base molds Thermo Scientific, USA 
Cell culture chamber slides BD Biosciences, USA 
Cell culture flasks (25cm2, 75cm2) Greiner Bio-One, Austria 
Cell culture plates (6-, 48-, and 96-well) Greiner Bio-One, Austria 
Cell culture plates (60mm, 100mm) Greiner Bio-One, Austria 
Cell scrapers BD Biosciences, USA 
Cover slides Carl Roth, Germany 
Falcons (15, 50ml) Greiner Bio-One, Austria 
Glassware  Duran, Germany 
Hemocytometer Marienfeld, Germany 
Multiwell plate Corning, USA 
Nitrocellulose membrane PALL, USA 
PCR 96-well plate, low profile Biorad, USA 
Pipette tips, filter tips (10, 100, 1000µl) Greiner Bio-One, Austria 
Plastic pipettes (5, 10, 25, 50ml) Greiner Bio-One, Austria 
Polyacrylamide gel electrophoresis glass plates Biorad, USA 
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Precellys ceramic kit (1,4; 2,8mm) Peqlab, Germany 
Reaction tubes (0,2ml) Biozym, Germany 
Reaction tubes (2; 1,5; 0,5ml) Eppendorf, Germany 
Superfrost plus slides Thermo Scientific,USA 
 
3.1.3 Animal experiments equipment and reagents 
 
Name Company 
16-gauge needles B Braun, Germany 
Animal ventilator, SAR-830/P Dwyer, USA 
Buprenorphine hydrochloride Essex Pharma, Germany 
Bepanthen Bayer Health Care, Germany 
Domitor Pfizer, USA 
Hemostatic clips Teleflex (Weck), USA 
Isoflurane Baxter, USA 
Ketamine (10%) Medistar, Germany 
Monocrotaline Sigma-Aldrich, USA 
NaCl solution B Braun, Germany 
Rymadyl Pfizer, USA 
Surgical instruments Aeskulap, Germany 
Stiches (Vicryl Plus) Ethicon, USA 
Syringes B Braun, Germany 
 
3.1.4 Kits 
 
Name Company 
BioRad DC Protein Assay BioRad, USA 
Sircol Collagen Assay Biocolor, UK 
RNeasy Fibrous Mini Kit  Qiagen, Germany 
ImProm-II Reverse Transcription kit  Promega, USA 
IQ™ Sybr Green Sypermix BioRad, USA 
Cell Proliferation ELISA, BrdU (colorimetric) Roche, Switzerland 
RNeasy  Mini Kit  Qiagen, Germany 
ProteoExtract Subcellular Proteome Extraction kit Merck (Calbiochem), Germany 
 
3.1.5 Chemicals 
 
Name Company 
2-butanol  Carl Roth, Germany 
Acetic acid (CH3COOH) Sigma-Aldrich, USA 
Acrylamid 30% (w/v) Sigma-Aldrich, USA 
Agarose Carl Roth, Germany 
Ammonium persulfate (APS) (NH4)2S2O8  10% (w/v) Sigma-Aldrich, USA 
Bovine serum albumin powder Carl Roth, Germany 
Bovine serum albumin solution (2 mg/ml) BioRad, USA 
Bromophenol blue  Merck, Germany 
Collagenase II Gibco, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, USA 
Disodium hydrogen phosphate (Na2HPO4) Carl Roth, Germany 
Dulbecco's Modified Eagle Medium (DMEM), 4,5g/l 
glucose  
Sigma-Aldrich, USA 
Ethanol, absolut Carl Roth, Germany 
Ethidium bromide Carl Roth, Germany 
Ethylenediaminetetraacetic acid (EDTA), 0.5M, pH 8.0 Carl Roth, Germany 
Fetal calf serum (Gold) PAA Laboratories, Austria 
Fluorescent  Mounting Medium Dako, Denmark 
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Glucose Carl Roth, Germany 
Glycerol  Sigma-Aldrich, USA 
Glycine Sigma-Aldrich, USA 
Hank's Balanced Salt Solution (HBSS) Gibco, USA 
HEPES Sigma-Aldrich, USA 
Hydrochloric acid (HCl) 37% Carl Roth, Germany 
L-glutamine Lonza, Switzerland 
Lithium Chloride (LiCl) Sigma-Aldrich, USA 
Loading dye for DNA electrophoresis (5x) Fermentas, USA 
Magnesium sulfate (MgSO4) Carl Roth, Germany 
Methanol Carl Roth, Germany 
Opti-MEM Glutamax I cell culture medium Gibco, USA 
Penicillin-streptomycin PAA Laboratories, Austria 
Pepsin Sigma-Aldrich, USA 
Phosphatases and proteases inhibitor cocktail Thermo Scientific, USA 
Phosphate buffered saline (PBS) PAA Laboratories, Austria 
Potassium chloride (KCl) Carl Roth, Germany 
Potassium di-hydrogen phosphate (KH2PO4) Carl Roth, Germany 
Radioimmunoprecipitation assay (RIPA) buffer (1x) Thermo Scientific, USA 
Rainbow™ Molecular Weight Marker GE healthcare, USA 
Rat fibroblasts cell culture medium Cell Applications, USA 
Restore Western Blot Stripping Buffer  Thermo Scientific, USA 
Skim milk powder Carl Roth, Germany 
Sodium chloride (NaCl) Carl Roth, Germany 
Sodium dihydrogen phosphate (NaH2PO4) Carl Roth, Germany 
Sodium dodecyl sulfate  (SDS)  Sigma-Aldrich, USA 
Sodium dodecyl sulfate (SDS)  20% (w/v) Carl Roth, Germany 
Sodium hydroxide (NaOH) 1M solution Merck, Germany 
Sodium hydroxide, pellets Carl Roth, Germany 
SuperSignal West Femto Chemiluminescent Substrate  Thermo Scientific, USA 
Tetramethylethylenediamine  (TEMED) Sigma-Aldrich, USA 
Tissue-Tek Sakura, USA 
Tris-HCl 0,5M, pH=6,8 Amresco, USA 
Tris-HCl 1,5M, pH=8,9 Amresco, USA 
Trizma-base Sigma-Aldrich, USA 
Trypsin/EDTA (10x) Lonza, Switzerland 
Water bath protection, Akasolv Carl Roth, Germany 
Wnt3a, recombinant R&D systems, USA 
Xtreme Gene transfection reagent Roche, Switzerland 
β-Mercaptoethanol  Sigma-Aldrich, USA 
 
3.1.6 Oligonucleotides 
Small interfering RNAs 
Two different predesigned siRNAs against β-catenin as well as scrambled siRNA were 
purchased from Qiagen, Germany. (#1: SI02012003, #2: SI02012010). Cy3-labeled 
scrambled siRNA was purchased from Ambion (Life Technologies, USA). 
siRNA Strand Sequence (5’-3’) 
β-catenin #1 Sense GUU UGA UAC CGA CCU GUA ATT 
 Antisense UUA CAG  GUC GGU AUC AAA CCA 
β-catenin #2 Sense GGG UGC GAU CCC ACG ACU ATT 
 Antisense UAG UCG UGG GAU CGC ACC CTG 
 
qRT- PCR primers 
All qRT-PCR primers were designed and purchased from Metabion (Germany). For primer 
sequences please see Appendix Table 1. 
3.1.7 Antibodies and cellular dyes 
For detailed list of primary and secondary antibodies used as well as cellular and nuclear 
dyes please see Appendix Tables 2-4. 
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3.2 Methods 
3.2.1 Animal experiments 
All pulmonary artery banding and monocrotaline experiments were performed on 250-300g 
weighting Sprague-Dawley (SD) rats purchased from Charles River (Sulzfeld, Germany).   
All experimental protocols involving animals were approved by Federal Authorities for 
Animal Research (Regierungspräsidium Darmstadt, Germany, AZ 17/2010, B2/191 and 
B2/285) and were performed by Dr med vet Wiebke Janssen, Julia Neuman and Uta Eule. 
Pulmonary artery banding of rats 
Rats were anesthetized with inhaled 1.5–2.0% Isoflurane, intubated and ventilated with 
oxygen. The thorax of animals was opened, a 16-guage needle was placed above the 
pulmonary artery and a suture was placed around both of them. Next, the needle was 
removed resulting in constriction of pulmonary artery to 1.7mm of diameter. Sham animals 
underwent the same operation excluding the banding procedure. All surgical procedures 
were performed under Isoflurane anesthesia (2.0% vol/vol) and an intraperitoneal 
administration of 0.06mg/kg buprenorphine hydrochloride. Two weeks after surgery, 
animals were sacrificed following organ harvest and/or cardiac fibroblasts isolation (see 
3.2.2). 
Monocrotaline-induced pulmonary hypertension model 
Monocrotaline was dissolved in 0.5M HCl and the pH adjusted to 7.4 with 0.5M NaOH.  
For induction of pulmonary hypertension in SD rats a single subcutaneous injection of 
monocrotaline (60mg/kg, Sigma Aldrich) was administered.  Control rats received an equal 
volume of isotonic saline instead. Organ harvest was performed at four, five and six weeks 
after saline/MCT injections. 
BAT-Gal reporter mice 
BAT-Gal reporter mice [107] were kindly provided by Dr. rer nat. Stefan Liebner (Johann 
Wolfgang Goethe-University, Frankfurt, Germany). BAT-Gal mice were anesthetized with 
inhaled 1.5–2.0% Isoflurane, intubated and ventilated with oxygen. After left sided upper 
thoracotomy pulmonary artery banding was applied using sterile hemostatic clips (Weck, 
USA). Sham-operated animals underwent the same procedure excluding clipping of the 
pulmonary artery. Tissue harvest was performed 2 weeks after operation. Both procedures 
were performed on genotyped positive mice 12-18 week of age. Wild-type mice and 
negative littermates were used.  
Right ventricular hypertrophy assessment 
For assessment of right ventricular hypertrophy the hearts were removed, the chambers 
were opened, and any excess blood was removed. After removal of atria and large blood 
vessels right ventricle wall was separated from left ventricle and septum. A ratio was 
determined based on the weight ratio of RV to LV plus septum.  
3.2.2 Cardiac fibroblast isolation 
 
For cardiac fibroblasts isolation Sham or PAB rats were anesthetized with 5 % (vol/vol) 
Isoflurane followed by i.p. injection of ketamine (90mg/kg) and domitor (0.1mg/kg). Hearts 
were harvested and further processed in sterile conditions. Right and left ventricles were 
separated and minced in sterile petri plates in cold 10ml 1x Ads buffer.  
 
5x Ads buffer (500 ml) 
NaCl 17g 
HEPES 11.9g 
NaH2PO4 0.3g 
Glucose 2.5g 
KCl 1g 
MgSO4 0.25g 
dd H2O up to 500ml 
pH adjusted to 7,35 with 1M NaOH 
 
Minced tissue was placed in upstanding 75cm2 cell culture flasks and washed with 1x Ads 
buffer. Next, tissue was subjected to repeated (3x) collagenase II digestion (0.5mg/ml; 2% 
trypsin in 1x Ads) for 20 min. in 37°C. Each fraction was then neutralized with fetal calf 
serum, centrifuged (1800 rpm) and subsequently resuspended in FCS. Finally all fractions 
were suspended in culture media (DMEM, 4.5mg glucose, 20% FCS; 0.1% 
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penicillin/streptomycin) and seeded in 75 cm2 culture flasks. Culture medium was changed 
24h after isolation and replaced with 10% FCS containing medium upon cell attachment 
and/or cell migration (1-2 weeks after isolation). Further culture was performed according 
to standard cell culture protocol, as described below. 
3.2.3 Cell Culture 
 
Rat cardiac fibroblasts from whole hearts were purchased from Cell Aplications (San Diego, 
USA) and grown on Fibroblast Growth Medium supplied by the company (RCF GF medium). 
For serum starvation, basal medium supplemented with 0.1% FCS was used (for collagen 
assays, apart from assays after siRNA treatment, medium did not contain any FCS). All cells 
used were in passage three to five. 
 
Right- and left-ventricular cardiac fibroblasts isolated from PAB- and Sham operated rats 
were maintained as decribed in 3.2.2 and characterized for fibroblast markers expression by 
qRT-PCR and IF staining techniques. All experiments were performed on cells in passage two 
to three. Cells were incubated in a humidified atmosphere of 5% CO2 in air at 37°C. 
 
3.2.4 siRNA-mediated β-catenin knockdown 
 
ß-catenin knockdown in rat cardiac fibroblasts was carried out using two different 
purchased siRNAs (Qiagen, Germany) and Xtreme-Gene transfection reagent (Roche, 
Switzerland) according to manufacturer’s instructions. Shortly, required amounts of siRNA 
and transfection reagent were diluted in Opti-MEM Glutamax I medium (Gibco, USA) and 
incubated together for 20 min with 1:5 ratio (µg siRNA: µl transfection solution).  Cells were 
transfected with 1-2µg siRNA (final concentration: 40-80nM) in Opti-MEM/Rat fibroblast 
medium (1:1) for 6h. Next, medium was replaced to appropriate growth medium 
(containing FCS and antibiotics) and cells were cultured for the next 24-48 h followed by 
RNA and protein isolations. For each experiment blank (medium only), mock (transfection 
reagent only) and negative (scrambled siRNA) controls were included.  Transfection 
efficiency was monitored using Cy3-labeled scrambled and anti-GAPDH siRNAs (Ambion, 
USA).  For that reason cells seeded in chamber slides were exposed Cy3-labeled siRNA (final 
concentration: 75-150nM, corresponding to 1-2µg siRNA per 6-well) according to the same 
protocol and incubated 24h. This was followed by cell fixation, slides mounting and 
visualization on confocal microscopy (general protocol described in 3.2.13.1). 
3.2.5 RNA isolation and cDNA synthesis 
 
Total RNA from heart tissues was isolated using RNeasy Fibrous Mini Kit (Qiagen, Germany) 
following manufacturer’s protocol. The procedure included proteinase K digestion step for 
removing abundant proteins in fiber-rich PAB right ventricles. 30 mg of heart tissue was 
used for each sample. Tissue was homogenized prior to isolation in RLT buffer (provided by 
kit) using Precellys homogenizer (Peqlab, Germany).  Total RNA from cells was isolated using 
RNeasy Mini Kit (Qiagen, Germany) following manufacturers protocol. RNA concentration 
and purity was determined using Infinite 200 PRO NanoQuant reader (Tecan, Switzerland). 
 
cDNA was synthesized by two step system using ImProm-II Reverse Transcription kit 
(Promega, USA) according to the manufacturer’s instructions. Briefly, 1µg of total RNA was 
incubated with 1µl oligo(dT) primers (total volume of 5µl) at 70°C for 5 min and next chilled 
on ice. Reverse transcription “master mix” was then prepared and added as follows: 
 
Reaction component Final concentration Volume 
ImProm-II. 5X Reaction Buffer 1x 4µl 
25 mM MgCl2 1.9 mM 1.5µl 
10 mM dNTP mix 0.5 mM 1µl 
RNasin® Ribonuclease Inhibitor (40U/μl) 20U 0.5µl 
ImProm-II. Reverse Transcriptase (1U/μl) 0.5U 1µl 
Nuclease free water - 7µl 
 
Samples were then subjected to cDNA synthesis by annealing step (25°C, 5min), synthesis 
step (42°C, 1h) and finally heat inactivation of reverse transcriptase (70°C, 15 min). cDNA 
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samples were then cooled on ice and their concentration and quality was determined using 
Infinite 200 PRO NanoQuant reader. 
 
3.2.6 Quantitative real time-PCR (qRT-PCR) 
 
700ng of newly synthesized cDNA (see 3.2.5) was then subjected to real-time polymerase 
chain reaction (qRT-PCR).  Specific intron-spanning primers were designed by using Primer3 
and Primer Blast programs and specificity of primers was once more cross-checked by 
blasting them against the whole genome (for primer details please see Appendix Table 1). 
The product size ranged between 150 and 200 bp. For qRT-PCR reactions IQ™ Sybr Green 
Sypermix (BioRad, USA) was used containing reaction buffer, hot-start iTaq DNA 
polymerase, 6mM MgCl2, Sybr Green and fluorescein as reference dye.  The reactions were 
prepared as follows: 
 
Reaction component Final concentration Volume 
IQ™ Sybr Green Sypermix 1x 12.5 µl 
Forward primer 200nM 0.5µl 
Reverse primer 200nM 0.5µl 
Nuclease free water - 9.5µl 
cDNA template 700ng 2µl 
 
To monitor reaction specificity, no template control (NTC) was included for each primer pair 
and melting curve was generated for each sample. The PCR reactions were performed in 
BioRad CFX96 Real Time System in the following conditions: 
 
       Step Temperature Time 
1. Initial denaturation 95°C 3min 
2. Denaturation 95°C 10s 
3. Annealing See App. Table 1 20s 
4. Elongation 72°C 30s 
5. Melting curve 65 - 95°C  - 
 
Repeat 
39x 
Threshold cycle (Ct) was determined for each sample. For comparison of expression levels, 
Ct values of gene of interest (GOI) were normalized to reference gene - Porphobilinogen 
Deaminase (PBGD) and expressed as ΔCt (Ct GOI – Ct reference). Alternatively, differences were 
expressed as ΔΔCt (ΔCt treated – ΔCt control). Each sample was loaded as duplicate and each 
experiment was repeated.  
 
3.2.7 Agarose gel electrophoresis of PCR products 
 
For verification of primer specificity, qRT-PCR products were mixed with 5x loading dye 
(Fermentas, USA) and separated on 1.5% agarose gel containing 5µl ethidium bromide in 
tris-acetate-EDTA (TAE) buffer. The DNA bands were detected by Gel iX Imager (Intas, 
Germany).   
 
TAE buffer component Final concentration 
Tris-HCl 40nM 
Acetic acid 40nM 
EDTA, 0.5M, pH 8.0 1mM 
 
 
3.2.8 Protein isolation 
 
For protein isolation from hearts, 100mg of tissue was homogenized in Precellys 
homogenizer (Peqlab, Germany) with 500µl RIPA buffer containing 1x protease and 
phosphatase inhibitor cocktail (Thermo Scientific, USA). Tissue homogenates were 
centrifuged 30 min at 14000 rpm and supernatants were transferred to new tubes.  
 
For protein isolation from cells, cell media was discarded and cells were carefully washed 
with PBS. PBS was then discarded and cells were incubated with appropriate amount of 
RIPA buffer containing proteases and phosphatases inhibitor cocktail (approximately 
7µl/cm2) for 10min in 4°C. Next, lysed cells were scratched with cell scrapers and lysates 
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were transferred to 1.5ml tubes. Cell lysates were then centrifuged 30 min at 14.000 rpm 
and transferred to new tubes. 
 
Protein concentration was measured using BioRad DC Protein Assay, which is based on 
Lowry’s protein detection method. A series of bovine serum albumin (BSA) solution with 
concentrations ranging from 0.1 to 2 mg/ml served as standard. For measurement, tissue-
derived proteins were diluted 40x and cell-derived proteins 3x prior to the measurement. 
Each sample was measured as duplicate using Infinite 200 PRO multiplate reader at 
λ=750nm.  
3.2.9 Protein fractionation 
 
For protein fractionation experiments rat cardiac fibroblasts were grown in 75cm2 flasks, 
serum-starved for 24 hours and stimulated with Wnt3a (2,5ng/ml) for 1,3 and 6 hours. 
Control samples were further starved for 6 hours. Next, cell media was removed and the 
cells were tripsinized, peleted and snap frozen until further use. Cells derived from two 
culture flasks were pooled together making up to approximately 3 million cells per sample. 
Each group was represented by two samples. Protein fractionation was then performed 
with a use of ProteoExtract® Subcellular Proteome Extraction Kit (Calbiochem, Germany) 
according to manufacturer’s instructions. Briefly frozen cell pellets were gently resuspended 
in ice-cold Extraction Buffer I and incubated for 10 min under agitation. The samples were 
centrifuged a 1000g for 10 min and supernatant was collected in a separate tube 
representing cytosolic fraction. The remaining pellet was resuspended in Extraction Buffer II 
and incubated for 30 min under gentle agitation. The samples were again centrifuged for 10 
min at 6000g and supernatant (membrane/organelle fraction) was collected in a separate 
tube. Insoluble pellet was resuspended in Extraction Buffer III, incubated for 10min and 
centrifuged at 7000g (10min). The supernatant (nuclear fraction) was collected in a separate 
tube and remaining pellet was discarded. All extraction buffers were provided by kit and 
mixed prior to use with protease inhibitor cocktail.  
 
Due to considerably high volumes of Extraction buffers it was necessary to concentrate the 
samples before further processing. This was performed by using Amicon Ultra centrifugal 
filter units (Milipore, USA) according to manufacturer’s instructions. Protein concentration 
was measured using BioRad DC Protein Assay (see 3.2.8) and further used in Western 
blotting (see 3.2.10). 
3.2.10 Western Blotting 
3.2.10.1 SDS-polyacrylamide (SDS-PAGE) gel electrophoresis 
 
After protein measurement protein concentration in each set of protein samples was 
equalized and equal amounts of protein were mixed with 5x sample buffer (SB): 
 
5x SB component Final concentration 
Tris-HCl (2M, pH 6.8)  375 mM 
SDS  10% (w/v) 
Glycerol  50% (v/v) 
β-Mercaptoethanol  12.5% (v/v) 
Bromophenol blue  0.02% (w/v) 
 
Next, samples were heat denatured at 100°C for 5 min. Samples were then loaded onto 10% 
polyacrylamide gels and run at 80-120 V until separated. Rainbow™ Molecular Weight 
Marker (GE Healthcare, USA) was included on each gel as molecular weight reference.  
 
Running buffer  component Final concentration 
Tris-HCl 20 mM 
Glycine 186 mM 
SDS 20% (w/v) 0.1% (w/v) 
 
 
Separating gel component Final concentration Volume 
Tris/Cl pH 8,9 [1.5M] 375 mM 1.5 ml 
Acrylamid 30% (w/v) 10% (w/v) 2 ml 
SDS 10% (w/v) 0.1% (w/v) 60 µl 
APS 10% (w/v) 0.05% (w/v) 30 µl 
TEMED 0.1% (v/v) 6 µl 
dd H2O - 2.4 ml 
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Stacking gel component Final concentration Volume 
Tris/Cl pH 6,8 [0.5M] 125 mM 625 µl 
Acrylamid 30% (w/v) 6% (w/v) 500 µl 
SDS 10% (w/v) 0.1% (w/v) 25µl 
APS 10% (w/v) 0.05% (w/v) 12.5µl 
TEMED 0.1% (v/v) 2.5 µl 
dd H2O - 1.34 ml 
 
 
3.2. 10.2 Immunoblotting 
 
The proteins separated on polyacrylamide gels were transferred onto nitrocellulose 
membranes using Mini Trans-Blot Electrophoretic Transfer Cell unit (BioRad, USA) for 1h at 
100V.  
 
Blotting buffer component Final concentration 
Tris-HCl 38mM 
Glycine 40mM 
Methanol 20% (v/v) 
 
 
Membranes were then blocked for 1h in 5% skim powder milk in 1x TBST and incubated 
overnight with indicated antibodies (see Appendix Table 2) solutions in 5% milk overnight at 
4°C with shaking. After three 10 min. washing steps in TBST membranes were incubated 
with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (see 
appendix Table 3) for 1h at room temperature (rt) on shaker. Three further TBST washing 
steps were then followed by developing with SuperSignal West Femto Chemiluminescent 
Substrate (Thermo Scientific, USA) and capturing the chemiluminescent signal in FujiFilm 
LAS 4000 analyzer (FijiFilm, Japan). Afterwards the antibodies were removed using Restore 
Western Blot Stripping Buffer (Thermo Scientific, USA) and membranes were reprobed with 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or ß-actin as loading controls. Each 
western blotting experiment was independently repeated.  
 
 
3.2.11 Sircol Collagen Assay 
 
For measuring salt-, acid-, and pepsin soluble collagen fractions in heart tissue, Sircol 
Collagen Assay was employed according to manufacturer’s instructions. 100mg of tissue 
was homogenized in RIPA buffer (with proteases and phosphatases inhibitors; Thermo 
Scientific, USA) in Precellys homogenizer (Peqlab, Germany). Next, each lysate was divided 
into three fractions, supplemented with PBS, 0.5M acetic acid or 0.1mg/ml pepsin (in 0.5M 
acetic acid) and incubated overnight at 4°C. For all further steps blanks (PBS, acetic acid or 
pepsin solutions were included). Acid Neutralizing Reagent was added to all acetic acid 
containing samples and subsequently Isolation and Concentration Reagent was added to all 
samples followed by overnight incubation at 4°C. All tubes were then centrifuged and the 
supernatant was carefully removed. For further steps standard solutions (pure collagen I, 2-
50 µg of collagen) were included. All samples were further incubated with 1ml Sircol Dye 
Reagent for 30 min. on shaker followed by centrifugation. Next, ice-cold Acid-Salt Wash 
reagent was applied and the samples were spun down. After removing of supernatant the 
pellet was resuspended in 400µl of Alkali Reagent, transferred as duplicates on multiwell 
plate and absorbance was measured at λ=555. 
 
For rat cardiac fibroblast collagen synthesis assay the protocol was modified by omitting 
acetic acid and pepsin digestion as well as concentration steps. For measuring collagen 
concentration in cell media, 1ml of media was concentrated overnight and further 
processed according to standard protocol.  
3.2.12 BrdU incorporation assay 
 
For cell proliferation measurements BrdU incorporation assay (Roche, Switzerland) was 
performed according to manufacturer’s instructions. Briefly, rat cardiac fibroblasts were 
grown on 96- or 48-well plates and incubated with given concentrations of Wnt3a, LiCl or  
β-catenin-targeting siRNA for 24-48h. For the two last hours of incubation BrdU labeling 
solution was added (final concentration 10 µM). This was followed by 30 min fixing and 90 
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min anti-BrdU antibody incubation steps. Next, antibody solution was removed, cells were 
washed with 1x PBS and incubated for 15-30 min with developing agent. Within this time 
frame colorimetric measurement was performed in Infinite 200 PRO multiplate reader at 
λ=450 nm (measurements at reference wavelength λ=690 nm were automatically 
subtracted for each well). For each study blank (- cells) and background (-medium, -BrdU) 
controls were included. 
3.2.13 Immunofluorescence staining 
 
3.2.13.1 Immunocytochemistry 
For immunocytochemical analysis, rat cardiac fibroblasts were fixed in ice-cold acetone-
methanol (1:1) solution for 10 min. at room temperature. The slides were then washed with 
1x PBS buffer and blocked with 5% BSA (w/v in 1xPBS) solution for 1h at RT. 
1x PBS component Final concentration 
NaCl 137mM 
KCl 2.7mM 
Na2HPO4 10mM 
KH2PO4 2mM 
pH adjusted to 7.4 with 1M NaOH  
 
Primary antibodies were diluted (see Appendix Table2) in 1-3% BSA in PBS and incubated 
overnight at 4°C. This was followed by 30 min. wash in 1xPBS buffer and 1h incubation with 
adequate fluorescent dye-labeled secondary antibody (1h, RT). After PBS wash step the 
nuclei was stained with Draq5 (Enzo Life Sciences, USA) for 10 min at RT, the slides were 
washed and mounted with Fluorescence Mounting Medium (Dako, Denmark). For 
immunofluorescence analysis Zeiss confocal microscope (Carl Zeiss, Germany) was used.  
3.2.13.2 Immunofluorescent cryosections staining 
For the analysis of protein localization in animal tissue appropriate organs were harvested 
and washed in cold HBSS (Gibco, USA) buffer. Prior to embedding the organs in Tissue-Tek 
(Sakura, USA) right ventricles were separated from left ventricles. Embedded samples were 
next snap-frozen in dry ice cooled 2-butanol and the cryoblocks were stored at -80°C. For 
immunofluorescent staining 6-10 µm thick sections were used and the same protocol as for 
immunocytochemistry was followed.  
If needed, counterstaining steps were included after secondary antibody and PBS wash 
steps were included as follows. For staining F-actin filaments the samples were incubated 
for 25 min. with Alexa488-labeled Phalloidin (1:40, Molecular Probes). Cell membranes 
were stained for 40 min. with Alexa488-labeled WGA (10ng/ml, Molecular Probes). 
Fibroblasts were visualized in the heart tissue by double staining with direct Cy3-labeled 
vimentin antibodies (1h, 1:300, Sigma -Aldrich). 
3.2.12.3 Immunofluorescent staining quantification 
 
The quantification of BAT-Gal positive cells as well as siRNA (Cy3-labeled) transfected cells 
was performed using STEPanizer© stereology tool, ver, 1.0 applet.  
3.2.13 Statistical analysis 
 
All results are expressed as means +/- standard error (SEM). Statistical analysis was 
performed using Student’s t-test for comparison of two groups and 1-way ANOVA with 
Newman-Keuls post hoc test for comparison of more than two groups. Differences between 
the groups was considered significant when P<0.05. 
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4. Results 
 
4.1 Cardiac hypertrophy and fibrosis in PAB and MCT models of right 
ventricular remodeling 
 
In the present study two animal models have been employed – pulmonary artery banding 
model of right ventricular hypertrophy and monocrotaline model of pulmonary 
hypertension with RV remodeling. Monocrotaline (MCT) is a pyrrolizidine alkaloid derived 
from the plant Crotalaria spectabilis. This phytotoxin is activated in the liver to the reactive 
monocrotaline pyrrole metabolite, which leads to vascular injury and subsequently to 
vascular remodeling and right ventricular hypertrophy. A single dose of MCT is sufficient to 
produce a progressive and sustained pulmonary hypertension in rats [108]. Pulmonary 
artery banding is based on the narrowing of internal diameter of the pulmonary artery and 
serves as a model of right ventricular hypertrophy and heart failure. This model does not 
exhibit any other direct effects on the heart apart from the increase in afterload. For this 
reason the changes observed PAB model result solely from the increased cardiac pressure 
overload (in contrast to other models of PAH, such as MCT model)[40]. 
Two weeks after PAB procedure and 4 to 6 weeks after monocrotaline injection hearts were 
harvested for further analysis (Fig. 8a). Preliminary examination of cardiac hypertrophy was 
conducted based on the RV to LV plus septum wet weight ratio. As shown in Fig. 8b, all 
treated animals developed significant RV hypertrophy.  In the MCT model, 5 weeks’ time 
point mostly resembled the results obtained for the PAB model and hence it was mainly 
subjected to further analysis.  
 Figure 8. Experimental setup for PAB and MCT models of right ventricular remodeling: a) hearts 
were collected 2 weeks after PAB (or Sham) procedure and 4-6 weeks after MCT (or NaCl) s.c. 
injection; b) hypertrophy was assessed by right ventricle to left ventricle plus septum (RV/LV+S) wet 
weight ratio. PAB n=10, MCT n=5-10; *** P<0.001 
 
Further, we investigated the expression of well-described hypertrophic markers by qRT-PCR 
technique in both models as well as cardiac fibrosis by changes in the total amount of 
collagen. We found upregulation of several hypertrophic markers in the right ventricles of 
PAB rats, including: αSKA, βMHC, BNP, ANP and TIMP (P<0.001). The level of αMHC was 
downregulated in agreement with the literature (P<0.01; see chapter 1.4). No significant 
changes in expression of genes associated with cardiac hypertrophy were observed in the 
left ventricles except the increased level of ANP. Additionally the expression of both, 
collagen type 1 and 3 was also significantly elevated in right ventricles of banded animals 
(P<0.001; Fig. 9a). 
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Figure 9. Assessment of right-ventricular hypertrophy after pulmonary artery banding by 
hypertrophic markers expression: a) qRT-PCR, and b) Sircol Assay. n=5 (a), n=10 (b), RV – right 
ventricle, LV - left ventricle; * (P<0,05); ** (P< 0,01); *** (P<0,001) vs. Sham 
 
For total collagen content measurement we employed sircol assay for three collagen 
fractions: salt, acid and pepsin soluble fractions corresponding to collagen crosslinking 
levels. We found an immense increase in acid-soluble fraction as well as significant increase 
in pepsin soluble fraction of total collagen in PAB right ventricles (Fig. 9b). Surprisingly we 
observed also an increase in pepsin soluble fraction in the left ventricles of PAB animals (Fig. 
9b).   
Expression profile alteration in the right ventricles of MCT animals resembled those 
obtained in PAB animals, including αSKA, βMHC, BNP, ANP, TIMP, Colα1 and Colα3 
upregulation (P<0.001-0.05) and αMHC downregulation (P<0.05; Fig. 10a). Also in this 
model, no change was observed in most hypertrophic markers expression in left ventricles 
besides αMHC downregulation (P<0.001) and ANP upregulation (P<0.001).  
Fig. 10. Assesment of right-ventricular hypertrophy after MCT treatment by hypertrophic markers 
expression: a) qRT-PCR, and b) Sircol Assay. n=5 (a), n=10 (b); RV – right ventricle, LV - left ventricle;  
* (P<0.05); ** (P< 0.01); *** (P<0.001) vs. Control 
 
The changes in total collagen in right ventricles of MCT rats were observed (P<0.5-0.001) 
within all fractions as compared to control. No significant differences in total collagen 
content were found in the left ventricles of MCT and control animals. Further, we assessed 
the cardiac fibrosis by immunofluorescence staining of vimentin, a reliable marker for 
identification of cardiac fibroblasts [32] and collagen type 1α. 
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Fig. 10. Assessment of right ventricular fibrosis after PAB by IF staining: Cryosections derived from 
PAB/Sham ventricles were stained for the presence of fibroblast marker - vimentin and collagen 1α 
(red). The sections were counterstained with Phalloidin (green) and Draq5 (blue) for cardiomyocyte 
and nuclei detection, accordingly. n=2, RV – right ventricle, LV - left ventricle, IgG – isotype control; 
bars represent 50 µm 
Right ventricles of PAB rats showed elevated levels of both, vimentin and collagen as 
compared to RVs of Sham animals (Fig. 10). In addition, no changes were observed in left 
ventricles within all groups (data not shown).  
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and collagen 1α (red). The sections were counterstained with Phalloidin (green) and Draq5 (blue) for 
cardiomyocyte and nuclei detection, accordingly; n=2, RV – right ventricle, LV - left ventricle, IgG – 
isotype control; bars represent 50 µm 
 
Similarly, right ventricles of MCT rats showed higher levels of vimentin and collagen staining 
as compared to controls (Fig. 11). However, we found also increased level of vimentin and 
collagen staining in the left ventricles of MCT animals (data not shown).  
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4.2 Wnt/β-catenin signaling molecules expression in PAB and MCT models 
 
To elucidate Wnt/β-catenin signaling molecules expression in hypertrophied hearts we 
performed mRNA and protein screening experiments in PAB and MCT models. The qRT-PCR 
analysis revealed upregulation of β-catenin, GSK3β and both Fz1 and Fz2 in the right 
ventricles of PAB animals (P<0.01, Fig. 12). Those changes were limited only to RVs and no 
alterations were observed within the left ventricles. 
 
Fig. 12. Wnt signaling molecules expression in heart homogenates derived from PAB animals: a) 
qRT-PCR, n=10; b) Western blotting analysis, n=5; and c) quantification of Western blotting by 
densitometry. RV - right ventricle; LV - left ventricle;  * (P<0.05); ** (P< 0.01); *** (P<0.005) vs. 
Sham 
 
Similarly, upregulation of β-catenin and GSK3β was observed on the protein level in PAB 
RVs (P<0.01, Fig. 12b-c). GSK3β phosphorylation levels were lower in both ventricles, but 
this reduction was not significant for the RVs. In MCT hearts (5 weeks after treatment) we 
observed an upregulation of GSK3β and Fz2 mRNAs (P<0.05, Fig.13a). β-catenin and Fz1 
receptor mRNAs showed the tendency to be upregulated but did not reach the statistical 
significance.  
 Fig. 13. Wnt signaling molecules expression in heart homogenates derived from MCT animals:  
a) qRT-PCR, n=10; b) Western blotting analysis, n=3; and (c) quantification of Western blotting  
by densitometry. RV - right ventricle, LV - left ventricle, 4w, 5w, 6w – 4, 5 and 6 weeks; * (P<0.05);  
** (P< 0.01); *** (P<0.005) vs. Control 
On the protein levels we also detected tendency to increase β-catenin and GSK3β in MCT 
model (especially in 4 week time points, Fig. 13b-c). Interestingly, although statistically not 
significant, those changes have been observed in both, the right and the left ventricle.  
4.3 Isolation and characterization of cardiac fibroblasts 
 
Since it was shown that Wnt/Fz signaling may influence the migration and the 
differentiation of cardiac fibroblasts [109], we decided to examine the role of this signaling 
pathway in the course of right ventricular hypertrophy. Primary cardiac fibroblast were 
isolated separately from right and left ventricles of PAB and Sham animals. The purity of 
isolation procedure was further confirmed by the expression of known fibroblast markers 
described in the literature [32]. All isolated cells were positive for fibronectin and collagen 
1α as assessed by immunofluorescence staining (Fig. 14a, expression of markers in LV- RCFs 
are not shown). 
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Fig. 14. Characterization of isolated primary cardiac fibroblasts I: a) representative pictures 
showing expression of fibroblast markers: fibronectin and collagen 1α in the right ventricular RCFs 
by IF, IgG – isotype control, bars represent 50 µm; b) bright filed pictures showing cardiac fibroblasts 
attaching to cell culture plate following isolation procedure (upper panel) and cells migrating out 
from the cardiac tissue particles (lower panel), bars represent 100 µm 
 
In addition, expression of fibroblast markers was analyzed in several successive passages of 
isolated cells. From passages 2 to 5, no changes have been observed in the expression of 
collagen 1α (Col1α1), fibronectin (Fn) and prolyl 4-hydroxylase β-subunit (P4Hb) (Fig. 15a). 
Expression of DDR2, a collagen receptor was slightly decreased in P5 (P<0.05) and collagen 
3α mRNA was decreased within passages 4 and 5 (P<0.05 and P<0.01, accordingly). In left 
ventricular RCFs only fibronectin was elevated in P4-P5 (data not shown). Based on these 
results all further experiments were performed on cells in passage 2 to 4. 
Further, proliferation of cardiac fibroblasts was determined by BrdU incorporation. We 
found increased proliferation of cardiac fibroblasts derived from right ventricles of PAB 
animals (P<0.005), whereas proliferation rates in other groups did not vary (Fig. 15b). 
 Fig. 15 Characterization of isolated primary cardiac fibroblasts II: a) Expression of fibroblast 
markers in right ventricular RCFs through passages (P2-P5) by qRT-PCR, n=3; b) assessment of RCFs 
proliferation by BrdU incorporation, n=10; and c) Expression of β-catenin and GSK3β in RCFs by qRT-
PCR. n=3; RV - right ventricle; LV - left ventricle * (P<0.05); ** (P< 0.01) *** (P<0.005) vs. Control 
 
Given that the right ventricle PAB rats show an increased expression of Wnt signaling 
components, further screening analysis of Wnt signaling molecules was assessed in cardiac 
fibroblasts to check whether cardiac fibroblasts may be, at least in part, responsible for 
observed changes. Indeed, β-catenin mRNA levels were significantly increased in PAB right 
ventricular fibroblasts (Fig. 15c, P<0.05). GSK3β levels were also increased in PAB RV-RCFs 
but this has not reached statistical significance.  
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4.4 Effects of Wnt3a stimulation on primary rat cardiac fibroblasts 
 
In order to examine how the Wnt pathway may act on cardiac fibroblasts we have designed 
series of experiments involving Wnt3a stimulation. In these fundamental experiments, we 
used the whole heart fibroblasts purchased from Cell Applications (USA). First, cardiac 
fibroblasts were treated with Wnt3a (2.5ng/ml) for 12 and 24 h followed by qRT-PCR 
analysis of changes in gene expression pattern. We found elevated mRNA levels of  
β-catenin and Dvl as well as GSK3β (Fig. 16a, P<0.01 and P<0.05, accordingly) 12h after 
Wnt3a stimulation. Apart from that we observed elevated levels of Axin2 - a negative 
regulator of the Wnt pathway, and Cyclin B1, responsible for G2/M transition, 12 and 24 h 
after stimulation with Wnt3a (P<0.01 in 12h and P<0.005 in 24h).  
 
Fig. 16. Wnt3a primary cardiac fibroblasts stimulation: a) 12-24h Wnt3a [2.5ng/ml] cardiac 
fibroblasts stimulation followed by qRT-PCR, n=4; b) 15-180 min Wnt3a [2.5ng/ml] stimulation 
followed by WB. n=2; (c) quantification of Western blotting by densitometry; * (P<0.05); ** (P< 0.01) 
*** (P<0.005) vs. Control 
 
Since the accumulation and nuclear translocation of β-catenin is the hallmark of activated 
canonical Wnt signaling, we decided to address this issue in cardiac fibroblasts treated with 
Wnt3a. Preliminary analysis of whole cell lysates has demonstrated accumulation of  
β-catenin in response to Wnt3a stimulation, which reached peak 1 hour after treatment 
(Fig. 16b-c; P<0.01). To further evaluate the nuclear translocation of β-catenin, cardiac 
fibroblasts stimulated for 1 to 6 h with Wnt3a were then submitted to protein fractionation 
procedure. We found increased levels of β-catenin in the nuclear fraction at 3 and 6 hours 
after Wnt3a treatment (Fig. 17a, 17b P<0.05 at 3h). Accumulation of β-catenin in cytosolic 
fraction was observed at 1 and 3 h (P<0.05), which roughly resembled the results obtained 
for whole cell lysates (Fig. 16b and 17a-b). The membrane fraction remained unchanged 
except a slight reduction in the level of β-catenin at 3 h post stimulation (Fig. 17a-b; 
P<0.05). All membranes were tested for the presence of contaminating proteins from other 
factions and have been proven to be pure (Fig 17c). 
 
Fig. 17. Subcellular localization of β-catenin assessed by protein fractionation: a) cardiac 
fibroblasts were stimulated with Wnt3a for 1-6h followed by protein fractionation and WB, n=2; b) 
quantification of Western blotting by densitometry; and (c) fractionation purity control. n=2; * 
(P<0.05) vs. Control 
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4.5 siRNA-mediated β-catenin knockdown 
 
In order to further explore the functional role of β-catenin in cardiac fibroblasts, we have 
established siRNA-mediated β-catenin knockdown experiments. To determine the 
transfection efficiency, whole heart cardiac fibroblasts were transfected with 1-2µg of Cy3-
labeled scrambled siRNA (Fig. 18a). Transfection efficiency was determined on the basis of 
siRNA-positive cells percentage. As illustrated in Figure 18a, cardiac fibroblasts transfection 
was observed at both concentrations of siRNA.  
 
 Fig. 18. siRNA mediated ß-catenin knockdown: a) transfection efficiency evaluation; 1-2 µg of Cy-3 
labeled scrambled siRNA (yellow) was used and visualized by immunofluorescence microscopy, 
counterstained with Draq5 (blue) and b) transfection efficiency quantification based on siRNA-
positive cells counting. n=2, ** (P<0.01 vs. 1µg). (c-e) β-catenin knockdown with  two different 
siRNAs (#1-2, 2µg, Qiagen) followed by c) qRT-PCR analysis; d) immunoblotting; and (e) 
quantification of Western blotting by densitometry. n=3, ** (P<0.01); *** (P<0.005) vs. negative 
control 
However, 2µg of siRNA showed better transfection efficiency as assessed by the amount of 
siRNA in cells (Fig. 18a) as well as the percentage of transfected cells (Fig. 18b, P<0.01). For 
that reason 2µg of siRNA was used in all further experiments. 
β-catenin knockdown was accomplished by using two different siRNAs (Qiagen, Germany) 
and was monitored using qRT-PCR technique. Both siRNAs significantly reduced β-catenin 
mRNA levels (Fig. 18c, P<0.001). To further confirm the knockdown, β-catenin protein levels 
were determined by Western blotting. On the protein level both siRNAs were able to 
significantly decrease the level of β-catenin (Fig. 18d-e, P <0.001). Transfection agent (mock 
control) as well as scrambled siRNA (negative control) had no effect on the levels of β-
catenin (Fig. 18c-e). Hence, we can conclude we have established efficient β-catenin 
knockdown. 
 
4.6 The impact of Wnt/β-catenin signaling on collagen production 
 
As it has been previously described that Wnt signaling may affect the synthesis of collagen 
in immortalized cardiac fibroblast cell line [109], we decided to investigate this 
phenomenon in primary rat cardiac fibroblasts. Wnt3a stimulation of RCFs resulted in 
upregulation of Collagens 1α, 3α (P<0.001) and Collagen 4α (P<0.01) at 12 and 24 h post 
treatment (Fig. 19a). Increased Collagen synthesis was also observed on the protein level 48 
hours after Wnt3a treatment as assessed by sircoll assay (Fig. 19b, P<0.001). Additionally, 
we also found increased collagen secretion as increased total collagen amounts were also 
detected in the culture medium from RCFs stimulated Wnt3a (P<0.01). These results were 
further confirmed using β-catenin knockdown approach. β-catenin depleted cells showed 
decreased collagen synthesis in basal (10% FCS) conditions as compared to scrambled siRNA 
negative control (P<0.01 and P<0.001 for siRNA #1 and #2, accordingly). Thus, these results 
indicate the functional role of Wnt/β-catenin signaling in the synthesis and secretion of 
Collagen by RCFs. 
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Fig. 19. The impact of Wnt/β-catenin signaling on collagen production: a) Collagen mRNA 
expression 12-24h after Wnt3a stimulation [2,5ng/ml] by qRT-PCR, n=4; b) Collagen synthesis and 
secretion 48h after Wnt3a treatment by sircoll assay, lysates n=10, medium n=5; and c) Collagen 
synthesis 48h after β-catenin siRNA-mediated knockdown in basal (10% FCS) conditions by sircoll 
assay. n=6; ** (P< 0.01); *** (P<0.005) vs. Control (a,b - serum starved cells, c - scrambled siRNA) 
 
4.7 The impact of Wnt/β-catenin signaling on RCFs proliferation 
 
Given that Wnt signaling pathway may contribute to increased production of collagen by 
cardiac fibroblasts, and thus can influence the development of cardiac fibrosis, we sought to 
test whether this effect can be further exerted by enhanced proliferation of these cells. For 
this purpose we examined the expression of pro-proliferative proteins and incorporation of 
BrdU in RCFs after stimulation with Wnt3a and knockdown of β-catenin. 
 Fig. 20. The impact of Wnt/β-catenin signaling on RCFs proliferation: RCFs proliferation was 
determined by (a, b) the expression of pro-proliferative proteins and (c, d) BrdU incorporation. a) 
Wnt3a RCFs stimulation [2.5ng/ml, 24h] followed by WB, n=4; b) quantification of Western blotting 
by densitometry; c) Wnt3a RCFs stimulation [2.5ng/ml, 24h] followed by BrdU incorporation assay, 
n=8; and d) β-catenin siRNA-mediated knockdown [2µg, 48h] followed by BrdU incorporation assay. 
n=6; ** (P< 0,01); *** (P<0,005) vs. Control (serum starved cells in a-c, scrambled siRNA in d) 
 
It was found that 24 h of Wnt3a stimulation was sufficient to increase the levels of 
expression of two Wnt/β-catenin downstream genes - cyclin D1 (P<0.01) and c-Myc 
(P<0.07), both of which positively regulate cell proliferation (Fig. 20a-b). Next, we defined 
proliferation of RCFs derived from the right and left ventricles of healthy rats in response to 
Wnt3a. In this experiment, lithium chloride treatment was included as a positive control. 
Lithium chloride is a GSK3β inhibitor and if Wnt3a activates the canonical Wnt signaling, it 
should resemble the results obtained for Wnt3a stimulation. Both, treatment with Wnt3a 
and LiCl resulted in a significant increase in BrdU incorporation of right ventricular 
fibroblasts (Fig. 20c, P<0.001). Surprisingly, in the left ventricular fibroblasts increased rates 
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of DNA synthesis that did not reach statistical significance were observed. Similarly, β-
catenin knockdown resulted in reduction in BrdU incorporation rates as compared to 
scrambled siRNA control (Fig. 20d, P<0.001). Collectively, this data shows that Wnt/β-
catenin signaling may also affect the proliferation of cardiac fibroblasts. 
 
4.8 Activation of Wnt signaling pathway in vivo 
 
The in vitro experiments strongly suggested the functional role of canonical Wnt signaling in 
right heart remodeling, or more specifically in cardiac fibrosis. To elucidate the role of this 
signaling pathway in vivo we recruited BAT-Gal reporter mice and subjected them to 
pulmonary artery banding procedure. BAT-gal mice carry a reporter gene - LacZ under a 
minimal TATA box promoter of the siamosis gene [107]. Upstream of the promoter, seven 
LEF/TCF-binding sites are inserted (Fig. 21a). After Wnt signaling activation, β-catenin 
together with LEF and TCF transcription factors binds to these sites, leading to the LacZ 
gene expression of the nuclear β-Galactosidase.  
We found β-Galactosidase-positive cells in both, PAB and Sham animals. Nevertheless, a 
significant increase of β-Galactosidase positive cells after PAB procedure when compared to 
other groups could be observed (Fig. 21b-c, P<0.05). Thus, activation of Wnt/β-catenin 
signaling pathway occurs in vivo and we can conclude that this signaling is important for the 
development of right ventricular remodeling and could eventually offer new treatment 
strategies. 
 Fig. 21. Pulmonary artery banding induced Wnt/β-catenin pathway activation: a) BAT-Gal mice 
carry 7 LEF/TCF binding sites (L) upstream of minimal promoter (TATA box) from siamosis gene and 
LacZ reporter gene; b) quantification of β-Galactosidase positive cells based on cell counting, n=4 ;  
* (P< 0.05); and c) representative images of β-Galactosidase (magenta) staining, counterstained with 
WGA (green) and Draq5 (blue). Scale bars represent 20µm 
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5. Discussion 
 
The main focus of this project was to elucidate the pathological processes underlying right 
ventricular remodeling. Pulmonary hypertension is one of the essential causes of this 
condition. In fact, right ventricular function is one of the major determinants of PAH 
patients’ survival [5]. In this project, we found elevated levels of several Wnt signaling 
pathway molecules in the hypertrophied right ventricles. Importantly, based on the results 
obtained from reporter mice we were able to associate activated Wnt pathway with the 
process of right ventricular remodeling. Further, our in vitro studies revealed cardiac 
fibroblasts as one of the possible targets of Wnt signaling contributing to myocardial 
hypertrophy. 
 
5.1 Cardiac hypertrophy in PAB and MCT models of right ventricular 
remodeling 
 
In the present study right ventricular hypertrophy was mimicked by two animal models: 
monocrotaline and pulmonary artery banding. The MCT model is characterized by vascular 
injury, which leads subsequently to vascular remodeling and right ventricular hypertrophy. 
The PAB model, on the other hand, does not exhibit any other direct effects on the heart 
apart from the increase in the afterload. The use of both aforementioned models allows the 
determination whether the observed changes are directly pressure-dependent or if they 
can be influenced by factors not attributable to pressure overload. Sprague-Dawley rats 
used in this project were subjected to PAB or MCT treatment followed by organ harvest 2 
and 4-6 weeks after procedure, accordingly. At the given time of the organ harvest both 
models were characterized by substantial right ventricular hypertrophy as assessed by 
RV/LV+S ratios. Further evaluation of RV hypertrophy in both models based on their 
expression of known genes related to RVH, we observed an upregulation of several 
hypertrophic markers in the right ventricles of PAB and MCT rats, including: αSKA, βMHC, 
BNP, ANP and TIMP and downregulation of αMHC, in line with the literature [31, 73, 76-78]. 
No significant changes in the expression of genes associated with cardiac hypertrophy were 
observed in the left ventricles except the increased level of ANP. This could be associated 
with advanced cardiac hypertrophy and ventricular interdependence, since elevated levels 
of ANP expression in the left ventricles have been already reported in the MCT model [110]. 
Importantly, collagen type 1 and 3 were significantly elevated in right ventricles of banded 
and MCT treated animals, suggesting myocardial fibrosis. Furthermore, a significant 
increase in acid-soluble as well as in pepsin soluble fraction of total collagen in PAB RVs 
whereas right ventricles of MCT rats showed elevated levels of all collagen (salt-, acid-, and 
pepsin- soluble) fractions. Surprisingly, we observed also an increase in pepsin soluble 
fraction in the left ventricles of PAB animals, which could be explained only through the 
indirect effects of right ventricular pressure overload on the left ventricle. Cardiac fibrosis in 
both models was further confirmed by immunofluorescence staining of vimentin and 
collagen type 1α. Right ventricles of PAB and MCT rats showed elevated levels of both, 
vimentin and collagen 1α as compared to RVs of appropriate control animals. No changes 
were observed in left ventricles of PAB animals but the left ventricles of MCT rats 
demonstrated elevated levels of vimentin and collagen 1α staining, pointing to the early 
fibrosis of the left ventricle of these animals (data not shown). This indicated a possible 
direct effect of monocrotaline on the heart. Monocrotaline model is often used in studies 
on PAH, because of its technical simplicity, reproducibility and low cost in comparison with 
other models. It has been previously speculated that RVH in this model is a direct 
consequence of the pressure overload. Recent reports indicate, however, that 
monocrotaline may have additional indirect effects on the heart. One of the major criticisms 
of MCT model is its ability to induce liver damage and hepatic veno-occlusive disease. It is 
also possible that the pro-inflammatory responses provoked by MCT-induced pulmonary 
vaculitis may contribute to the development of heart failure [108]. In fact, Akhavein et al. 
observed an impairment of the left ventricular function associated with diffuse myocarditis 
in rats treated with MCT [111]. In contrast, Chen et al. have not observed any fibrotic 
changes or inflammatory infiltrations in the left hearts of MCT rats [112]. These results 
indicate that the use of MCT model in studies on right ventricular hypertrophy may need to 
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be complimented or verified in exclusive models right ventricular hypertrophy. For this 
reason further experiments, except for the screening of Wnt signaling molecules, have been 
carried out only on samples from the PAB model. 
 
5.2 Wnt/β-catenin signaling molecules expression in PAB and MCT models 
 
As Wnt/β-catenin signaling has been previously implicated to maladaptive growth of the left 
ventricle we sought to elucidate expression of its molecules in hypertrophied hearts. The 
qRT-PCR analysis revealed upregulation of β-catenin, and two Frizzled receptors: Fz1 and 
Fz2 in the right ventricles of PAB animals. Interestingly, also mRNA levels of GSK3β were 
elevated in RVs followed PA banding. Those changes were limited only to RVs and no 
alterations were observed within the left ventricles. Similarly, upregulation of β-catenin and 
GSK3β was observed on the protein level in PAB RVs. GSK3β phosphorylation levels were 
lower in both ventricles, but this reduction was not significant for the RVs. In MCT hearts (5 
weeks after treatment) we found upregulation of GSK3β and Fz2 mRNAs. β-catenin and Fz1 
receptor mRNA levels showed the tendency to be upregulated but did not reach the 
significance level. On the protein levels we also detected tendency in higher levels of β-
catenin and GSK3β in the MCT model (especially in 4 week time points). Interestingly, 
although statistically not significant, those changes have been observed in both, the right 
and the left ventricles. This again indicated that observed changes in monocrotaline model 
might not be specific to cardiac hypertrophy but induced directly by MCT. Additionally, the 
MCT model revealed distinct GSK3β phosphorylation at 5 and 6 weeks post treatment.  
β-catenin was shown to be stabilized upon hypertrophic stimuli in left ventricle, which 
involves the inhibition of GSK3β kinase activity [104]. Our results showing upregulation of  
β-catenin levels on mRNA and protein levels in PAB model are in line with this study. 
Unfortunately monocrotaline animals presented only a tendency in β-catenin upregulation. 
GSK3β levels in both models showed some discrepancies, which to some extent are also 
seen in studies on the left ventricle. Our observations indicate that the level of GSK3β 
increases in response to pressure-overload, at least in the pulmonary artery banding 
induced right heart hypertrophy. This was also shown in transverse aortic constriction (TAC) 
induced left ventricular remodeling [113]. This and other studies addressed also 
phosphorylation status of GSK3β under stress conditions, showing GSK3β S9 
phosphorylation-dependent inactivation in hypertrophied hearts, at least at one week after 
TAC [104, 113]. Our study revealed rather contradictory results concerning the 
phosphorylation of GSK3β namely, in the PAB model a decrease in phosphorylation of this 
protein was observed, while a significant increase in phosphorylation of GSK3β was 
observed in MCT model. Since cardiac hypertrophy in the MCT model in secondary to 
pulmonary vascular remodeling it is possible that other humoral factors can contribute to 
GSK3β inactivation in this model. On the other hand, since GSK3β phosphorylation is 
present in both ventricles, one can’t exclude that MCT can trigger those changes directly 
acting on the heart. Interestingly, in human hearts, inhibition of GSK3β was seen in the end-
stage heart failure, but was not observed in compensated hypertrophy [103]. Thus, 
observed discrepancies might also account to differences in hypertrophic stage despite 
similar hypertrophic ratios. Further experiments measuring actual GSK3β kinase activity in 
those samples should be undertaken to confirm these findings. Nevertheless, we can 
conclude that several Wnt signaling molecules are upregulated during hypertrophic 
response of the right ventricle pointing to possible involvement of this pathway in the 
cardiac remodeling. 
 
5.3 Cardiac fibroblasts characterization and Wnt3a stimulation 
 
To determine whether the observed changes in expression of Wnt signaling molecules in 
the pressure-overloaded right ventricles arise at least in part due to altered expression 
patterns of cardiac fibroblast, we have established a protocol for isolation of these cells 
from the right and left ventricle separately. To our knowledge this is a first study comparing 
right and left ventricular fibroblasts under pressure-overload conditions. Fibroblast 
phenotype of isolated cells was confirmed based on specific fibroblasts marker expression 
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by immonocytochemical and qRT-PCR analysis. Importantly, most of fibroblast markers 
expression remained unchanged through passages 2 to 5, including Col1α1, Fn and P4Hb, 
except DDR2 and Col3α1.  
In order to assess differences between individual populations of cardiac fibroblasts (RV vs. 
LV, PAB vs. Sham) we have measured proliferation rates of these cells based on BrdU 
incorporation. We observed increased proliferation rates of cardiac fibroblasts derived from 
right ventricles of PAB animals (P<0.005) in basal (10% FCS) conditions whereas 
proliferation rates in other groups did not vary. Increased proliferation of RV-PAB 
fibroblasts may be explained by mechanical stress as well as humoral stimulation associated 
with pressure overload. Along this line, we found significantly increased β-catenin mRNA 
levels in right ventricular fibroblasts derived from PAB rats. GSK3β levels were also 
increased in PAB RV-RCFs but this has not reached significance level. This pointed to the 
possible effects of Wnt/β-catenin signaling on cardiac fibroblasts during myocardial 
remodeling and its involvement in hyperproliferation status of RV-PAB fibroblasts. In order 
to examine how the Wnt signaling could influence cardiac fibroblasts we stimulated RCFs 
with Wnt3a, traditionally considered to activate Wnt canonical pathway [86]. Cardiac 
fibroblasts treated with Wnt3a displayed elevated mRNA levels of β-catenin and Dvl as well 
as GSK3β 12h after Wnt3a stimulation. Additionally expression of Axin2 - a negative 
regulator of the Wnt pathway, and Cyclin B1, responsible for G2/M transition, was 
significantly increased 12 and 24 h after Wnt3a treatment.  
As β-catenin expression is largely regulated at the protein level we wanted to determine its 
accumulation in whole cell lysates after treatment with Wnt3a. Stimulation of cardiac 
fibroblasts with Wnt3a produced a distinct accumulation of β-catenin, which reached peak 
level 1 h after treatment. Additionally, corresponding accumulation of Dvl has been 
observed. Activation of Wnt signaling typically involves Dvl protein phosphorylation that can 
be observed as a mobility shift when blotted with total-Dvl antibody. Interestingly, in our 
experiment, Wnt3a RCFs stimulation resulted mainly with an increase in the overall level of 
Dvl, whereas its phosphorylation was only slightly increased in response to Wnt3a. Thus,  
it is possible that Wnt signaling, at least in cardiac fibroblasts, can also influence Dishevelled 
stability. Nevertheless, additional experiments using specific p-Dvl antibodies should be 
performed to confirm Dvl activation in response to Wnt3a stimuli.  
Since the nuclear translocation of β-catenin is the hallmark of activated Wnt canonical 
signaling, we sought to address this issue by protein fractionation of cell lysates derived 
from Wnt3a stimulated cardiac fibroblasts. We found β-catenin accumulation in cytosolic 
fraction 1 and 3 hours after Wnt3a treatment, which resembled the results obtained for 
whole cell lysates. Subsequently β-catenin translocated to the nucleus (at 3-6 hours post 
stimulation, P<0.05 at 3h). The membrane fraction remained unchanged except a weak 
reduction in the level of β-catenin at 3 h post stimulation. 
Thus, we can confirm that cardiac fibroblasts derived from pressure-overloaded right hearts 
exhibit different characteristics in comparison to fibroblasts derived from Sham animals. 
Those differences may be associated with Wnt signaling, since the mRNA levels of β-catenin 
in PAB-RV cardiac fibroblasts were significantly increased. 
 
5.4 The impact of Wnt/β-catenin signaling on collagen production 
 
Cardiac fibrosis is an important component of the remodeling of the heart and can 
eventually lead to myocardial stiffening and failure. Collagen deposition and turnover play a 
primary role in this pathological process [32, 49]. Since our previous experiments pointed 
the possible impact of canonical Wnt pathway on right ventricular RCFs, we tested if this 
signaling could influence the synthesis and secretion of collagen by cardiac fibroblasts. 
Wnt3a stimulation of RCFs resulted in upregulation of collagens 1α, 3α and collagen 4α 
mRNA levels at 12 and 24 h post treatment. Increased collagen synthesis was also observed 
on the protein level 48 h after Wnt3a treatment. Additionally, Wnt3a stimulation induced 
collagen secretion as increased total collagen amounts were also detected in the culture 
medium from RCFs stimulated with Wnt3a. These results were further confirmed using β-
catenin knockdown approach. β-catenin depleted cells showed decreased collagen 
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synthesis in basal (10% FCS) conditions as compared to scrambled siRNA negative control. 
Similar effect of Wnt signaling on collagen synthesis has been previously described in 
immortalized cardiac fibroblast cell line [109]. However to date, genes encoding collagens 
have not been revealed as direct downstream genes of β-catenin. It is therefore intriguing 
to speculate that the participation of other proteins may mediate the activation of collagen 
synthesis. Wnt1-induced secreted protein-1 (WISP1) is a promising candidate gene, which 
may be involved in this process. WISP-1 is a member of connective tissue growth factor and 
nephroblastoma overexpressed family of growth factors shown to play a role in cellular 
growth and survival. It has been shown that the Wnt1 and β-catenin signaling leads to 
elevated expression of WISP-1 [114]. Recently, Colston et al. [115] showed WISP-1 
upregulation in the heart post myocardial infarction, resulting in myocardial hypertrophy, 
fibroblast proliferation, and increased collagen synthesis. Therefore, the exact molecular 
mechanism by which Wnt signaling can generate excessive collagen synthesis need to be 
addressed in future. Nevertheless, our results clearly indicate the functional role of Wnt/β-
catenin signaling in the synthesis and secretion of Collagen by RCFs. 
 
5.5 The impact of Wnt/β-catenin signaling on RCFs proliferation 
 
Both, enhanced ECM protein synthesis of individual fibroblasts and fibroblast proliferation 
can contribute to the development and progression of myocardial fibrosis [32]. Our primary 
results using immunodetection of fibroblast marker – vimentin in rat hearts showed 
increased fibroblast density in PAB RVs suggesting that cardiac fibroblast proliferation can 
also take place in the pressure induced cardiac remodeling. Additionally we observed an 
increased BrdU incorporation of cardiac fibroblasts derived from right ventricles of banded 
animals (P<0.005) in vitro, whereas DNA synthesis rates in other groups did not vary. This 
was in line with other report showing higher H3-thymidine incorporation by non-myocyte 
cells in isoproterenol-induced cardiac hypertrophy [116]. It has been also suggested that 
pericytes and bone marrow-derived cells can contribute to the myocardial fibroblast 
population [117].  
 
In order to elucidate if Wnt signaling could also influence cell growth we examined the 
expression of pro-proliferative proteins and incorporation of BrdU in cardiac fibroblasts 
after stimulation with Wnt3a and siRNA-mediated knockdown of β-catenin. Two Wnt/β-
catenin downstream genes - Cyclin D1 and c-Myc (positively regulating cell proliferation) 
were elevated 24 h after Wnt3a stimulation. Similarly, Wnt3a increased BrdU incorporation 
rates of cardiac fibroblasts. Lithium chloride treatment exerted the same effect suggesting  
that observed proliferation of RCFs is triggered by activation of Wnt canonical pathway.  
DNA synthesis rates of the left ventricular fibroblasts were only slightly elevated after 
Wnt3a or LiCl treatment. Interestingly the LV-RCFs BrdU incorporation rates were 
significantly greater than that observed for RV-RCFs in basal conditions and after treatment.  
The observed differences could be due to different properties of the two populations of 
fibroblasts. As the pulmonary circulation is of low pressure, right ventricular fibroblasts are 
normally exposed to less stress as compared to fibroblasts in the left ventricles. This could 
explain the greater rate of incorporation of BrdU in the LV-RCFs in basic conditions and their 
lower reactivity to Wnt3a stimulation. Indeed, distinct growth characteristics and 
proliferative responsiveness was already described in atrial versus ventricular fibroblasts 
[118]. In agreement with our previous results, β-catenin knockdown resulted in reduction  
in BrdU incorporation rates as compared to scrambled siRNA control (P<0.001). 
Interestingly, Ueda et al. [119] showed that Wnt signaling does not directly affect 
proliferation of rodent fibroblasts, but inhibits apoptosis of these cells in low serum 
conditions. In this study, the authors used fibroblast cell lines, which have completely 
different growth characteristics in comparison to primary cardiac fibroblasts, which may 
explain the differences in results obtained in both studies. In addition, knockdown of β-
catenin exerting an inhibitory effect on fibroblast proliferation was carried out in medium 
containing 10% FCS. Collectively, this data indicates that Wnt/β-catenin signaling affects the 
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proliferation of cardiac fibroblasts in vitro. Still, future studies should clarify the role of 
Wnt/β-catenin signaling in apoptosis of cardiac fibroblasts. 
 
5.6 Activation of Wnt signaling pathway in vivo  
 
Since in vitro experiments strongly suggested the functional role of canonical Wnt signaling 
in right heart remodeling we sought to elucidate the role of this signaling pathway in vivo.  
For this purpose BAT-Gal reporter mice were recruited and subjected to pulmonary artery 
banding procedure. Wnt signaling activation can be easily visualized in those mice by 
nuclear  
β-Galactosidase staining. We found β-Galactosidase-positive cells in both, PAB and Sham 
animals. Nevertheless, a significant increase of β-Galactosidase positive cells after PAB 
procedure when compared to other groups could be observed. Thus, activation of Wnt/β-
catenin signaling pathway occurs in vivo and we can conclude that this signaling is 
important for the development of right ventricular remodeling and could eventually offer 
new treatment strategies. 
 
5.7 Conclusions  
 
In the present study, the components of Wnt canonical signaling, including its key mediator 
β-catenin, have been shown to be increased in pressure-overloaded hearts as well as in 
cardiac fibroblasts derived from those hearts. In vitro, we have been able to show that 
canonical Wnt signaling can trigger both, cardiac fibroblast proliferation and collagen 
synthesis and that those effects are dependent on β-catenin, as its knockdown exerts 
opposite effects. We have demonstrated that pressure overload is sufficient to induce Wnt 
signaling in vivo, ultimately confirming the role of this signaling pathway in cardiac 
remodeling. The main findings of this study are summarized in Figure 22. However,  
the precise molecular mechanism underlying those processes needs extensive 
investigations. Taken all together we can conclude that Wnt signaling is important for the 
development of right ventricular remodeling and may eventually offer innovative treatment 
strategies.  
 
 
Fig. 22 Schematic summary of changes seen in cardiac fibroblasts derived from pressure-
overloaded hearts. Pulmonary artery banding resulted in activation of Wnt pathway in vivo. In 
cardiac fibroblasts activated Wnt signaling leads to increased levels of collagen synthesis and 
elevated proliferation rates of those cells. This in turn may lead to the development of myocardial 
fibrosis influencing mechanical properties of the hypertrophied hearts.  
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6. Outlook  
 
The current study shows that Wnt signaling plays a significant role in right ventricular 
remodeling. However, more research on this topic needs to be undertaken before the 
precise molecular mechanism underlying this process becomes clearly understood.  
Some discrepancies were observed in the basic screening studies between the PAB and MCT 
models. The main difference was observed in the level of phosphorylation of GSK3β. As the 
MCT model turned out to be little suitable in studies on right ventricular hypertrophy,  
it would be advisable to include another animal model of pulmonary hypertension with RVH 
(e.g. Sugen5416/Hypoxia model) might be included in the study. In addition, since the 
GSK3β phosphorylation affects its activity, an additional experiment on its kinase activity 
would also add some information. 
In our study, we showed that Wnt/β-catenin signaling can regulate collagen expression in 
cardiac fibroblasts. However to date, genes encoding collagens have not been revealed as 
direct downstream genes of β-catenin. To elucidate, if this phenomenon depends on  
β-catenin co-transcriptional activity, one could use RCFs stably transduced with dominant 
negative LEF-1. Additionally, it would be of interest to evaluate WISP-1 levels in the right 
ventricles of PAB animals, since this molecule was previously shown to influence cardiac 
fibrosis and hypertrophy post infarction. 
As for the studies on the cardiac fibroblasts proliferation, two additional experiments 
should be carried out. First, a confirmation of cardiac fibroblast proliferation on heart 
sections (e.g. PCNA or Ki-67 staining) would clarify if proliferating RCFs are distributed 
equally throughout the myocardium or do the cluster (e.g. in  the perivascular areas 
pointing to possible involvement of circulating cells in cardiac fibrosis). Furthermore, 
subjecting RCFs (Wnt stimulated versus β-catenin-siRNA treated) to apoptosis assay could 
finally confirm that observed changes in the cell count are due to increased proliferation 
and not survival. 
Finally, more extensive in vivo studies should ultimately confirm the role of Wnt signaling in 
cardiac remodeling and present new therapeutic possibilities. As the reporter mice 
experiments were conducted on a limited number of animals, the number of mice used in 
trials should be significantly increased. As we have observed some basal activation of Wnt 
signaling in Sham operated mice, one can’t exclude a “leaky” expression in those animals. 
Therefore reporter mice experiments should be further confirmed on transgenic animals. Of 
particular interest would be mice expressing non-degradable (removed exon 3) or non-
functional (removed exon3-6) version of β-catenin in fibroblasts. According to our 
hypothesis performing pulmonary artery banding on those mice should lead to 
deterioration or improvement of cardiac function, accordingly. Lastly, performing animal 
studies with the use of Wnt signaling inhibitors (e.g. Tankyrase) could finally lead to the 
development of novel therapeutic strategies against right ventricular hypertrophy and 
fibrosis. 
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Right ventricular remodeling refers to changes in size, shape and function of the right heart 
after cardiac injury. It is a progressive disorder connected to several conditions, including 
pulmonary hypertension. It is also a leading predictor for the development of right heart 
failure and death. Nonetheless, until recently the importance of right ventricular function in 
health and disease has been often underestimated. Previous studies showed that Wnt 
signaling pathway plays an important role in left ventricular remodeling in response to 
hypertrophic stimuli. While all of the available literature describes the impact of this 
signaling cascade in maladaptive growth of the left ventricle, its role in the right heart 
hypertrophy is unknown. Given that, we hypothesized that canonical Wnt signaling could 
also play a role in the development of right heart hypertrophy. As the Wnt pathway is 
crucial for the development of right ventricle we speculated its contribution to RVH could 
be more prominent.  
In this study, we employed and characterized the PAB and MCT animal models of right 
ventricular hypertrophy. Both models presented with substantial right heart hypertrophy as 
judged by RV/LV+S ratios as well as mRNA expression of known hypertrophic markers. 
Additionally, the right ventricles of PAB and MCT animals showed advanced fibrotic 
changes.  
We were able to show an upregulation of several Wnt signaling molecules, including  
β-catenin, GSK3β and Frizzled receptors on mRNA level in hypertrophied right ventricles  
of PAB animals. Most importantly, β-catenin and GSK3β protein levels were also elevated in 
those animals. Similarly, we found increased mRNA levels of GSK3β and Fz2 receptor in the 
right ventricles of MCT rats. β-catenin and GSK3β protein levels showed a tendency to be 
elevated in those animals but did not reach significance level. Furthermore we found a 
significant upregulation in β-catenin expression in cardiac fibroblasts derived from right 
ventricles of PAB animals as compared to Sham-RVs implying that CFs could be at least in 
part responsible for observed changes. Based on BrdU incorporation experiments, we also 
found that right ventricular fibroblasts exhibit increased proliferation rates. To further 
elucidate if this increased proliferation could be dependent on activated canonical Wnt 
signaling we performed several experiments employing Wnt3a stimulation and siRNA 
mediated β-catenin knockdown.  
The hallmark of Wnt canonical pathway is the accumulation and nuclear translocation of β-
catenin. We could show both, accumulation of β-catenin in the cytoplasm as well as 
increased β-catenin nuclear levels in RCFs stimulated with Wnt3a. Wnta3a-mediated 
activation of Wnt signaling resulted further in the upregulated expression of several genes, 
most prominently Axin2 and Cyclin B1. We could further link Wnt/β-catenin signaling with 
elevated collagen synthesis as well as increased cardiac fibroblast proliferation, two 
fundamental processes of myocardial fibrosis. We showed that Wnt3a stimulation leads to 
elevated mRNA levels of Collagens 1, 3 and 4 as well as total collagen synthesis in RCFs. 
Additionally we could observe increased collagen secretion.  In accordance, siRNA-mediated 
β-catenin knockdown resulted in decreased collagen expression. We further showed that 
Wnt3a stimulation was sufficient to increase the levels of expression of two Wnt/β-catenin 
downstream genes - Cyclin D1 and c-Myc, both of which positively regulate cell 
proliferation. Likewise, Wnt3a stimulation and LiCl treatment resulted in significantly 
elevated rates of BrdU incorporation as compared to control. Finally, β-catenin knockdown 
resulted in reduction in DNA synthesis rates as compared to scrambled siRNA control. 
In order to confirm our findings in vivo we recruited BAT-Gal reporter mice and subjected 
them to pulmonary artery banding procedure. Activation of Wnt-canonical pathway was 
assessed by β-Galactosidase nuclear staining of cryosections derived from those animals. 
Although β-Galactosidase positive cells were present in all included groups, we observed a 
substantially greater amount of those cells in the right ventricles of rats subjected to PAB. 
Thus, activation of Wnt/β-catenin signaling pathway occurs in vivo and we can conclude 
that this signaling is important for the development of right ventricular remodeling and 
could eventually offer new treatment strategies. 
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Rechtsventrikuläres Remodeling bezeichnet die Veränderungen von Größe, Form und 
Funktion des rechten Herzens nach Herzschädigung oder veränderten hämodynamischen 
Verhältnissen. Es ist eine fortschreitende Erkrankung, die mit mehreren Krankheiten, 
einschließlich pulmonaler Hypertonie (PH), verbunden ist. Es ist auch ein führender 
Indikator für die Entwicklung des rechten Herzversagens und Tod. Dennoch wurde bis vor 
kurzem die Bedeutung der rechtsventrikulären Funktion in Gesundheit und Krankheit oft 
unterschätzt. Frühere Studien zeigten, dass der Wnt-Signalweg eine wichtige Rolle bei dem 
linksventrikulären Remodeling spielt. Während die gesamte vorhandene Literatur die 
Auswirkungen dieser Signalkaskade in maladaptivem Wachstum des linken Ventrikels 
beschreibt, ist seine Rolle in der Hypertrophie des rechten Herzens bislang unbekannt. 
Daher stellten wir die Hypothese auf, dass der kanonische Wnt-Signalweg auch eine Rolle 
bei der Entwicklung der rechtsventrikulären Hypertrophie spielt.  
In dieser Studie haben wir Tiermodelle der rechtsventrikulären Hypertrophie verwendet 
und charakterisiert (PAB, pulmonalarterielles Banding; MCT, Monocrotalin induzierte PH). 
Beide Modelle zeigen eine erhebliche Hypertrophie des rechten Herzens, was durch 
Erhöhung des RV/LV+S Verhältnisses sowie durch mRNA-Expression von bekannten 
hypertrophen Markern charakterisiert ist. Zusätzlich zeigen rechte Ventrikel aus beiden 
Tiermodellen fortgeschrittene fibrotische Veränderungen. 
Wir konnten eine Hochregulation von mehreren Wnt-Signalmolekülen, darunter β-Catenin, 
GSK3β und Frizzled-Rezeptoren, auf mRNA-Ebene in hypertrophierten rechten Ventrikeln 
der PAB Tieren zeigen. Auf Proteinebene konnten wir erhöhte Mengen an β-Catenin und 
GSK3β nachweisen. Ebenso fanden wir erhöhte mRNA-Spiegel von GSK3β und Fz2 
Rezeptoren in den rechten Ventrikeln von MCT-Ratten. β-Catenin und GSK3β 
Proteinmengen zeigten in diesem Modell allerdings nur eine Tendenz der Erhöhung. 
Darüber hinaus fanden wir eine signifikant erhöhte Expression von β-Catenin in kardialen 
Fibroblasten aus der rechten Herzkammer der PAB Tieren im Vergleich zu Sham-RVs, was 
bedeutet, dass diese Zellen, zumindest zum Teil, verantwortlich für die beobachteten 
Veränderungen sein könnten. Basierend auf BrdU-Inkorporation Experimenten, haben wir 
herausgefunden, dass die rechte Herzkammer eine erhöhte Proliferation von Fibroblasten 
aufwies.  
Das Kennzeichen des kanonischen Wnt-Signalwegs ist eine Akkumulation und 
Kerntranslokation von β-Catenin. Wir zeigten sowohl die Akkumulation von β-Catenin im 
Zytoplasma als auch erhöhte β-Catenin Lokalisation im Kern nach Stimulation mit Wnt3a. 
Wnta3a-vermittelte Aktivierung der Wnt-Signalweg führte weiter in die hochregulierten 
Expression verschiedener Gene, besonders Axin2 und Cyclin B1. Wir konnten weiterhin den 
Wnt/β-Catenin-Signalweg mit erhöhter Kollagen-Synthese sowie mit erhöhter kardialer 
Fibroblasten-Proliferation (zwei grundlegender Prozesse der myokardialen Fibrose) 
verknüpfen. Die Wnt3a Stimulation führt zu erhöhter Expression der Kollagene 1, 3 und 4 
sowie der gesamten Kollagensynthese in kardialen Fibroblasten Ebenfalls führte der siRNA-
vermittelte β-catenin-Knockdown zu einer verminderten Kollagen Expression. Weiterhin 
zeigten wir, dass eine Wnt3a Stimulierung ausreichend war, um das Niveau der Expression 
von zwei Wnt/β-catenin regulierten Genen, nämlich Cyclin-D1 und c-Myc, die beide positive 
Regulatoren der Zellproliferation sind, zu erhöhen. Ebenso ergab Wnt3a Stimulierung und 
LiCl Behandlung signifikant erhöhte Raten des BrdU- Inkorporation im Vergleich zur 
Kontrolle. Schließlich führte der β-Catenin-Knockdown zu einer Verringerung der DNA-
Synthese im Vergleich zur Kontrolle. 
Um unsere Befunde in vivo zu bestätigen, wurden BAT-Gal Reporter-Mäuse einer 
Pulmonalarterien-Stenose (PAB) unterzogen. Die Aktivierung des kanonischen Wnt- Wegs 
wurde durch β-Galactosidase Kernfärbung von Kryoschnitten von diesen Tieren beurteilt. 
Obwohl β-Galactosidase-positive Zellen in allen Gruppen anwesend waren, stellten wir eine 
wesentlich größere Menge dieser Zellen in den rechten Ventrikeln von PAB Ratten fest. 
Somit erfolgt die Aktivierung der Wnt/β-Catenin-Signalweg in vivo und wir können 
feststellen, dass dieses Signal wichtig für das Remodeling des rechten Ventrikels- ist, was 
therapeutisch genutzt werden kann.  
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Table 1. List of real-time primers 
Gene Primer sequence Annealing  T  
[˚C] 
Product 
size 
αCAA F: GCC AGC CCA GCT GAA CCC AG 59 200 bp 
 R: ATG ACA CCC TGG TGG CGT GG   
αMHC F: CGG ACA CTG GAG GAC CAG GC 60 121 bp 
 R: GCC TAG CCA GCT CGC CGT TC   
αSkMA F: GGC ACC CAG GGC CAG AGT CA 60 177 bp 
 R: TGACACCCTGGTGACGGGGC   
ANP F: GAT GGA GGT GCT CTC GGG CG 59 181 bp 
 R: TTC GGT ACC GGA AGC TGT TGC AG   
Axin2 F: GAC GCG CTG ACC GAC GAT TCC 60 192 bp 
 R: AGC AGG TTC CAC GGG CGT CA   
ß-catenin F: TCA GAT CTT AGC TTA CGG CAA 60 134 bp 
 R: TTG TTG CTA GAG CAG ACA GAC   
βMHC F: ACCGGAGAATCCGGAGCTGGT 60 120 bp 
 R: CAA GGT GCC CTT GCC TGG GG   
BNP F: CAG CTG CCT GGC CCA TCA CT 59 167 bp 
 R: GCT CCA GCA GCT TCT GCA TCG T   
Col1α1 F: AGA TGG TCG CCC TGG ACC CG 60 120 bp 
 R: GGG ACA CCT CGT TCT CCA GCC T   
Col3α1 F: CCC TGC TCG GAA TTG CAG AGA CC 59 166 bp 
 R: CCG CGG GAC AGT CAT GGG AC   
Col4α1 F: ATG GAA TCC CGG GGT CGG CA 60 184 bp 
 R: GGG CCG GGA GGA CCC ATG AA   
Col8α1 F: TTC CAC GGT CCT CTC CGT GGG 59 114 bp 
 R: CAA TGG GGC TGG GTC CCG TC   
Cyclin B1 F: TGC GAA CCA GAG GTG GAA CTG GA 60 132 bp 
 R: TTC GGC AGG TGC ACA TCC AGA TGT   
DDR2 F: AAC CAG CCT GTC CTG GTG GC 59 157 bp 
 R: TGC AGA GCG GGT CCT CAG TG   
Dvl1 F: TGA TGA GGC TGC CCG GAC CA 60 154 bp 
 R: GCT CAG CCG GCT CGT GTT GT   
Fn1 F: TGG AGC CAG GAA CCG AGT ACA CC 60 191 bp 
 R: AGG GTT GGT GAC GAA GGG GGT   
Frizzled1 F: CGT ACT GAG TGG AGT GTG TTT TG 60 188 bp 
 R: TGA GCT TTT CCA GTT TCT CTG TC   
Frizzled2 F: TAC CTG TTC ATC GGC ACA TC 60 143 bp 
 R: GTG TAG AGC ACG GAG AAG ACG   
GSK3ß F: ACT TTG TGA CTC AGG AGA ACT 60 141 bp 
 R: TCG CCA CTC GAG TAG AAG AAA   
P4H3α F: CTA CTG CTC CAG CCC GCA CG 59 152 bp 
 R: TGC TTT TCC CCT GAA GCC ACC A   
P4Hß F: ACA AAC CGG AGT CAG ACG AGC TG 59 102 bp 
 R: GCA GTT CCT GGC TCA TCA GGT GG   
PBGD F: ATG TCC GGT AAC GGC GGC 58 135 bp 
 R: CAA GGT TTT CAG CAT CGC TAC   
TIMP F: AGT TTC TCA TCG CGG GCC GT 59 144 bp 
 R: ACA CTG TGC ACA CCC CAC AGC   
 
Table 2. List of primary antibodies 
 
Primary antibody Source Dilution  
WB 
Dilution  
IF/IHC 
Company 
αSMA Mouse  1:200 Sigma Aldrich 
ß-actin Mouse 1:5000  Sigma Aldrich 
ß -catenin Rabbit 1:1000 1:100 Cell Signaling 
ß -Galactosidase Rabbit  1:100 Abcam 
c-Myc Rabbit 1:1000  Cell Signaling 
Collagen 1α1 Mouse  1:70 Meridian Life 
Sciences 
CyclinD1 Rabbit 1:200  Santa Cruz 
Dvl-2 Rabbit 1:200  Santa Cruz 
Fibronectin Rabbit  1:200 Abcam 
GAPDH Mouse 1:5000  Novus Biologicals 
GSK3ß - p(S9) Rabbit 1:1000  Cell Signaling 
GSK3ß  total Rabbit 1:200  Santa Cruz 
HDAC1 Rabbit 1:500  Cell Signaling 
Hsp90 Rabbit 1:500  Epitomics 
PDGFRß Rabbit 1:200  Santa Cruz 
PLCß Rabbit 1:1000  Cell Signaling 
PLCß(p) Rabbit 1:1000  Cell Signaling 
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Vimentin-Cy3  Mouse  1:300 Sigma Aldrich 
 
 
 
Table 3. List of secondary antibodies 
 
Secondary antibody Dilution Company 
Alexa  555-conjugated anti-mouse Ab 1:1000 Molecular Probes 
Alexa 488-conjugated  anti-rabbit Ab 1:1000 Molecular Probes 
Alexa 488-conjugated anti-mouse Ab 1:1000 Molecular Probes 
Alexa 555-conjugated anti-rabbit Ab 1:1000 Molecular Probes 
HRP-conjugated anti rabbit Ab 1:1000 Dako cytomation 
HRP-conjugated anti-mouse Ab 1:30000 Sigma Aldrich 
 
Table 4. List of cellular dyes 
 
Dye Dilution Company 
Alexa 488-conjugated Phalloidin 1:40 Molecular Probes 
Alexa 488-conjugated WGA 10ng/ml Molecular Probes 
DAPI 1:1000 Molecular Probes 
Draq5 nuclear stain 1:500 Enzo Life Sciences 
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